• Pseudomonas aeruginosa;
  • Haemophilus influenzae;
  • Staphylococcus aureus;
  • Burkholderia ssp.;
  • mutator;
  • adaptive radiation


  1. Top of page
  2. Abstract
  3. Introduction
  4. Pathophysiology of CF lung disease
  5. Pathophysiology of COPD
  6. Bacterial colonization of the CF lung
  7. Bacteria colonization in COPD
  8. Antimicrobial treatment for CF patients
  9. Antimicrobial treatment for COPD patients
  10. Concluding remarks
  11. Acknowledgements
  12. References

Cystic fibrosis (CF), the most common autosomal recessive disorder in Caucasians, and chronic obstructive pulmonary disease (COPD), a disease of adults, are characterized by chronic lung inflammation, airflow obstruction and extensive tissue remodelling, which have a major impact on patients' morbidity and mortality. Airway inflammation is stimulated in CF by chronic bacterial infections and in COPD by environmental stimuli, particularly from smoking. Pseudomonas aeruginosa is the major bacterial pathogen in CF, while in COPD, Haemophilus influenzae is most frequently observed. Molecular studies indicate that during chronic pulmonary infection, P. aeruginosa clones genotypically and phenotypically adapt to the CF niche, resulting in a highly diverse bacterial community that is difficult to eradicate therapeutically. Pseudomonas aeruginosa clones from COPD patients remain within the airways only for limited time periods, do not adapt and are easily eradicated. However, in a subgroup of severely ill COPD patients, P. aeruginosa clones similar to those in CF persist. In this review, we will discuss the pathophysiology of lung disease in CF and COPD, the complex genotypic and phenotypic adaptation processes of the opportunistic bacterial pathogens and novel treatment options.


  1. Top of page
  2. Abstract
  3. Introduction
  4. Pathophysiology of CF lung disease
  5. Pathophysiology of COPD
  6. Bacterial colonization of the CF lung
  7. Bacteria colonization in COPD
  8. Antimicrobial treatment for CF patients
  9. Antimicrobial treatment for COPD patients
  10. Concluding remarks
  11. Acknowledgements
  12. References

Cystic fibrosis (CF) is the most common autosomal recessive disorder in Caucasians, affecting ∼1 : 2500 children, with a carrier frequency of 1 : 25. In the CF lung, disease develops as a consequence of mutations in the CF transmembrane conductance regulator (CFTR) gene, which encodes a membrane-bound cAMP-regulated chloride channel (Kerem et al., 1989; Riordan et al., 1989; Rommens et al., 1989). The primary structure of CFTR indicates that it belongs to a family of transmembrane proteins called ATP-binding cassette transporters, which form a large family of proteins responsible for the translocation of a variety of compounds across membranes of both prokaryotes and eukaryotes. CFTR is composed of five domains: two membrane-spanning domains, two nucleotide-binding domains (NBDs) and a regulatory domain. Over 1500 mutations and sequence variants have been described to date and reported to the Cystic Fibrosis Genetic Analysis Consortium. Most of these mutations are rare and only four mutations occur at a frequency of >1%. The most frequent mutation, F508del, occurs in the DNA sequence that codes for the NBD1 (Döring & Ratjen, 2005). Abnormal transport of chloride and sodium ions caused by CFTR mutations affects water movement across epithelia, leading to pathophysiological consequences in various organs including the respiratory, gastrointestinal and reproductive tract, the pancreas and the liver. The CF phenotype is rather heterogeneous due to many different mutations in CFTR and the influence of modifier genes (Davies, 2007). Chronic respiratory infections caused by several opportunistic bacterial pathogens are recognized to have the largest impact on morbidity and mortality in CF patients (Høiby & Frederiksen, 2000). Bacterial infections stimulate inflammatory defence mechanisms, leading to tissue destruction and extensive tissue remodelling (Döring & Ratjen, 2007). The resulting emphysema and fibrosis mainly determine the reduced life expectancy in individuals with CF. Once established, these infections are difficult to treat with antibiotics and the pathogens are rarely eradicated (Döring et al., 2004).

Unlike CF, chronic obstructive pulmonary disease (COPD), a chronic, progressive disorder of lung parenchyma and airways, is exclusively a disease of adults, especially of individuals over the age of 60 years. COPD is the fourth leading cause of death globally, accounting for approximately 2.7 million deaths in 2003 (Lopez et al., 2006). COPD is defined by airflow obstruction that is not fully reversible, in contrast to asthma, which is associated with reversible airflow obstruction (Celli & MacNee, 2004). The degree of reduction in forced expiratory volume in 1 s (FEV1) is used to classify COPD into four stages (mild, moderate, severe and very severe). Although genetic factors influence COPD (Wood & Stockley, 2006; Silverman et al., 2009; Smolonska et al., 2009), these influences are complex and mostly unknown. COPD results from responses to environmental stimuli, particularly from smoking, in genetically susceptible individuals (Celli & MacNee, 2004; Wood & Stockley, 2006). Bacterial pathogens also play an important role in the course and pathogenesis of COPD (Sethi & Murphy, 2008).

Many similarities exist between CF and COPD. In both diseases, exuberant inflammation causes airflow obstruction, tissue destruction and extensive tissue remodelling, leading to emphysema and fibrosis. Thus, inflammation plays an important role in the morbidity and mortality of patients. However, CF and COPD differ with regard to infection. While the role of chronic bacterial infections, particularly caused by Pseudomonas aeruginosa, is well established in CF (Høiby & Frederiksen, 2000), the impact of these infections in patients with COPD is less clear (Murphy et al., 2008). Furthermore, pathogens such as Moraxella catarrhalis and Streptococcus pneumoniae are frequently observed in patients with COPD (Sethi & Murphy, 2001), and yet are seldom present in the airways of CF patients. Because of improved symptomatic treatment strategies and antibiotic therapy, the prognosis of CF individuals has improved considerably and many children now reach adulthood. While antibiotic therapy is beneficial in treating acute exacerbations of COPD (Anthonisen, 2002; Ram et al., 2006), this therapy has not been demonstrated to affect the course of the disease. In this review, we will discuss the pathophysiology of lung disease in CF and COPD, bacterial colonization of airways and the complex genotypic and phenotypic adaptation processes of the opportunistic bacterial pathogens in these diseases and novel treatment options.

Pathophysiology of CF lung disease

  1. Top of page
  2. Abstract
  3. Introduction
  4. Pathophysiology of CF lung disease
  5. Pathophysiology of COPD
  6. Bacterial colonization of the CF lung
  7. Bacteria colonization in COPD
  8. Antimicrobial treatment for CF patients
  9. Antimicrobial treatment for COPD patients
  10. Concluding remarks
  11. Acknowledgements
  12. References

A variety of innate immune functions have been reported to be dysregulated in CF, and a number of mechanisms have been put forward to explain the fact that practically every CF patient suffers from chronic bacterial lung infections. The inability of mutated CFTR to effectively secrete chloride from respiratory epithelial cells into the airway surface liquid causes excessive water absorption from the airway surface liquid, leading to impaired mucociliary clearance in individuals with CF (Matsui et al., 1998; Boucher, 2007) (Fig. 1). This in turn facilitates the colonization of the viscous mucus layer on the respiratory epithelium with bacteria, rather than the colonization of the epithelial surface per se (Ulrich et al., 1998; Worlitzsch et al., 2002). Furthermore, an abnormal accumulation of ceramide in the lungs of CF mice and in epithelial cells from CF patients has been shown to result in an increased death rate of respiratory epithelial cells and DNA deposits on the respiratory epithelium, which facilitates bacterial adherence (Teichgräber et al., 2008). In addition to these mechanisms, which explain the high incidence of chronic bacterial lung infections in CF, other investigators have demonstrated that alveolar macrophages from CF mice exhibit defective killing of internalized P. aeruginosa (Di et al., 2006). After phagocytosis by alveolar macrophages, bacteria enter the phagosome and lysosomes, exhibiting a low pH due to CFTR and vacuolar ATPase, and fuse with the phagosome, forming the phagolysosome. The mature organelle exhibits an acid pH that ensures the final destruction of the ingested bacteria by a variety of proteolytic enzymes. Defective CFTR-dependent acidification of lysosomal pH (Barasch et al., 1991) has been linked to significant survival of P. aeruginosa (Di et al., 2006). The contribution of CFTR to the regulation of pH in intracellular organelles has been discussed controversially (Haggie & Verkman, 2007, 2009) due to experimental difficulties to ensure targeting of identical vesicle populations by pH-sensitive fluorescent dyes. Pseudomonas aeruginosa infection may also be facilitated in CF airways directly by defective CFTR, which, in its functional state, binds the pathogen within lipid rafts and removes it from the epithelial surface via internalization (Pier, 2000).


Figure 1.  Bacterial killing mechanism of innate immunity in the respiratory tract of CF patients and healthy individuals. (a) In healthy individuals, bacteria entering the mucus layer overlaying the respiratory epithelium are effectively removed from the airways by a functional mucociliary clearance system and killed by CAMPs derived from submucosal glands or epithelial cells, by functional neutrophils (PMN) or macrophages (MΦ) or within epithelial cells after uptake via functional CFTR. (b) In individuals with CF, defective CFTR leads to a highly viscous mucus layer that impairs mucociliary clearance, the migration of CAMPs, neutrophils and macrophages towards the bacterial targets, the uptake of bacteria by CFTR itself, and induces a pH shift to alkaline values in epithelial lysosomes. Because of ceramide accumulation, this results in DNA deposits, which in turn serve as adhesion matrices for bacteria. A similar pH shift in the phagolysosomes of macrophages impairs bacterial killing. Ceramide accumulation also triggers cytokine release, which induces further neutrophil influx (adapted from Döring & Gulbins, 2009).

Download figure to PowerPoint

The viscosity of the secretions has several further negative consequences for the pathophysiology of CF lung disease. These secretions are present in submucosal gland ducts of CF patients as a result of mutated CFTR (Engelhardt et al., 1992), and may impair the transport of antimicrobial oligopeptides (Lehrer & Ganz, 2002; Selsted & Quellette, 2003) onto the epithelium (Verkman et al., 2003; Joo et al., 2004) (Fig. 1). They may also negatively affect the migration of neutrophils towards the pathogens within the mucus overlaying the respiratory epithelium (Matsui et al., 2005) (Fig. 1). This may allow bacterial multiplication and profound changes in the bacterial phenotypes that facilitate chronic infection. Furthermore, within the highly viscous mucus, a microaerobic/anaerobic milieu prevails due to oxygen consumption by bacterial pathogens such as P. aeruginosa (Worlitzsch et al., 2002; Hassett et al., 2009) or invading neutrophils (Kolpen et al., 2010). Consequently, the generation of reactive oxygen species (ROS) by neutrophils and other cells is abolished and bacterial killing is impaired (Fig. 2a and b), particularly with regard to pathogens, which are intrinsically resistant to nonoxidative killing, or capable of changing their phenotype towards resistance to nonoxidative killing.


Figure 2.  Bacterial sensitivity and resistance to neutrophil-mediated killing in aerobic and anaerobic environments. (a) On the respiratory epithelium of healthy individuals, neutrophils effectively kill the CF-related bacterial pathogens Pseudomonas aeruginosa (red), Staphylococcus aureus (blue) and Burkholderia cepacia (green) by ROS and CAMPs. (b) Neutrophils in the anaerobic milieu in the mucus layer overlaying the respiratory epithelium in individuals with CF are devoid of ROS, leading to intraneutrophil survival of S. aureus (blue), which produces a protective exopolysaccharide coat (red), and B. cepacia (green), which is intrinsically resistant to nonoxidative killing (adapted from Döring & Gulbins, 2009).

Download figure to PowerPoint

Lung inflammation is a key finding in patients with CF (Konstan et al., 1994). While ceramide accumulation has been shown to induce a proinflammatory status in the respiratory tissue of CF mice, which precedes bacterial infection, including an increased production of cytokines and recruitment of macrophages (Teichgräber et al., 2008), inflammation clearly increases considerably in response to persistent bacterial infections. The exaggerated inflammatory response dominated by neutrophils not only facilitates tissue destruction but also induces tissue remodelling (Döring & Gulbins, 2009; Ulrich et al., 2010). An essential role in these pathogenic reactions is related to the imbalance of serine and metalloproteases to their respective inhibitors (Döring, 1999; Ratjen et al., 2002). Particularly, neutrophil elastase has been implicated in the pathophysiology of CF lung disease. The serine protease has been shown to cleave the endogenous serine protease inhibitor α1-antitrypsin, immunoglobulins, surfactant proteins, complement components and a variety of cell receptors (Döring & Gulbins, 2009). Cleavage of the complement receptor 1 on neutrophils and the activated complement component C3bi on opsonized bacteria creates an ‘opsonin-receptor mismatch’ (Berger et al., 1989; Tosi et al, 1990), which significantly impairs P. aeruginosa killing.

The vicious cycle of persisting bacterial pathogens, encased in biofilms, and decaying neutrophils leads to increasing endobronchial DNA deposition and large mucus plugs, which further obstruct the airways of the patients (Whitchurch et al., 2002; Worlitzsch et al., 2002).

Pathophysiology of COPD

  1. Top of page
  2. Abstract
  3. Introduction
  4. Pathophysiology of CF lung disease
  5. Pathophysiology of COPD
  6. Bacterial colonization of the CF lung
  7. Bacteria colonization in COPD
  8. Antimicrobial treatment for CF patients
  9. Antimicrobial treatment for COPD patients
  10. Concluding remarks
  11. Acknowledgements
  12. References

The pathophysiology of COPD is characterized by chronic inflammation of airways as a result of active and passive smoking (Barnes, 2000; Celli & MacNee, 2004). The indices of airway inflammation – increased neutrophils, IL-8, TNF-α and neutrophil elastase – are all increased compared with healthy controls (Keatings et al., 1996; Hill et al., 1999a b; Barnes et al., 2003). Chronic colonization of the airways contributes to this airway inflammation (Hill et al., 2000; Parameswaran et al., 2009). However, the degree of airway inflammation does not reach the threshold of patient-perceived symptoms. When airway inflammation crosses this threshold for short episodes, these are called exacerbations (Hill et al., 1999a, b). The course of COPD is punctuated by episodes of acute exacerbations, which are associated with increased airway inflammation compared with baseline levels (Hill et al., 1999a, b; Sethi et al., 2008). Goblet cell hyperplasia and mucus hypersecretion are present in the airways of most COPD patients, especially in those with clinical features of chronic bronchitis (Barnes, 2000). Although mucus viscosity is considerably lower in COPD compared with CF, mucociliary clearance of bacterial pathogens may be impaired by the fact that respiratory epithelial cells lose cilia and undergo squamous metaplasia (Hogg & Timens, 2009). Lung inflammation leads to the activation of innate immune cells, particularly macrophages, which have a profound effect on immune cell recruitment into the airways and tissue remodelling (Barnes, 2004). In the small airway walls, infiltrating neutrophils and lymphocytes cause airway thickening and remodelling, resulting in reduced airway diameter and airflow (Hogg et al., 2004). Inflammatory cellular infiltration of alveolar walls is associated with the destruction of alveoli and enlargement of air spaces, i.e. emphysema (Cosio et al., 2009). Infiltration especially by CD8+ lymphocytes occurs in pulmonary vessel walls that are thickened due to increased collagen deposition (Cosio et al., 2009). As in CF, chronic lung inflammation is accompanied by an imbalance between proteases and antiproteases in COPD (Stockley, 1999). Furthermore, oxidative stress is persistently enhanced (Rahman & MacNee, 1996) as well as a number of other innate immune functions that lead to tissue remodelling (Barnes, 2000; Cosio et al., 2009; Hogg & Timens, 2009). Alveolar macrophages from COPD patients have decreased sensitivity to nontypeable Haemophilus influenzae (NTHI) antigens and decreased ability to phagocytose NTHI, compared with normal controls (Berenson et al., 2006a, b). The structural abnormalities in airways, alveoli and pulmonary vasculature vary among COPD patients (Hogg & Timens, 2009).

Bacterial colonization of the CF lung

  1. Top of page
  2. Abstract
  3. Introduction
  4. Pathophysiology of CF lung disease
  5. Pathophysiology of COPD
  6. Bacterial colonization of the CF lung
  7. Bacteria colonization in COPD
  8. Antimicrobial treatment for CF patients
  9. Antimicrobial treatment for COPD patients
  10. Concluding remarks
  11. Acknowledgements
  12. References

Chronic bacterial pulmonary infection leading to an irreversible decline in lung function is the main cause of mortality and morbidity in CF patients, with >95% of deaths due to respiratory failure (Dodge et al., 2007). Staphylococcus aureus is the most prevalent opportunistic bacterial pathogen, which chronically infects CF airways in the age group of 0–9 years (55%), while P. aeruginosa is the most prevalent pathogen thereafter (81%) (Høiby & Frederiksen, 2000). At a much lower prevalence, H. influenzae, S. pneumoniae, Escherichia coli, strains of the Burkholderia cepacia complex (Bcc), comprising 10 genomovars, and fast-growing mycobacteria can be present in airway specimens of CF patients (Høiby & Frederiksen, 2000).

In addition, a large number of strict anaerobes have been detected, which may be surprising for an air-filled organ such as the lung. However, the viscous mucus plugs, in which all these bacteria thrive, have been shown to create microaerobic/anaerobic conditions (Worlitzsch et al., 2002), which favour the growth of anaerobes. Anaerobic bacteria have been detected in significant numbers (>105 CFU mL−1) in the lungs of CF patients using classic culturing methods, indicating that a highly diverse bacterial community is present within the CF lung (Brook & Fink, 1983; Jewes & Spencer, 1990; Tunney et al., 2008; Worlitzsch et al., 2009). These include diverse species belonging to the genera Prevotella, Bifidobacterium, Veillonella, Peptostreptococcus and Fusobacterium. Single obligate anaerobic species persisted for up to 11 months in sputum plugs in vivo (Worlitzsch et al., 2009). Whether these bacteria contribute to the pathophysiology of CF lung disease is still an open question. CF patients with and without obligate anaerobes in sputum specimens did not differ in lung function (Worlitzsch et al., 2009).

Culture-independent profiling methodologies (Nocker et al., 2007) such as terminal restriction fragment length polymorphism have considerably advanced our knowledge of the polymicrobial nature of CF lung disease (Rogers et al., 2003, 2004, 2006, 2009; Harris et al., 2007; Bittar et al., 2008; Sibley et al., 2008, 2009; Klepac-Ceraj et al., 2010). For instance, it has been shown by culture-independent methods that the Streptococcus milleri group of viridans streptococci, comprising Streptococcus constellatus, Streptococcus intermedius and Streptococcus anginosus, is present in CF sputum specimens and related to the pathophysiology of CF lung disease (Sibley et al., 2008).

During acute infections, which may resolve after several days, microorganisms reversibly regulate gene expression by responding to environmental signals, and thereby adapt their phenotypes accordingly (Green & Paget, 2004; Gilles-Gonzalez & Gonzalez, 2005). During the course of chronic infections, which may last >10 years, however, mutants can be selected that differ genotypically and phenotypically from the originally infecting strain. Given the large microbiota in the airways of infected CF patients, complex interactions not only occur between microorganisms and the environment but also among members of the community that use primary or secondary metabolites in a multitude of chemical interactions (Duan et al., 2009). A fascinating view is that ‘cheater’ cells that refrain from producing ‘expensive’ metabolites benefit in such communities from those produced by the rest of the population (Keller & Surette, 2006; Duan et al., 2009). The chemical and physical nature of the mucus plugs in CF airways, in which the bacterial pathogens multiply, favours such a microevolution during the course of chronic infection. Interestingly, it has been found that the number of taxa and the phylogenetic diversity and evenness within the microbiota in the airways of CF patients decrease with age, which has been attributed to either repeated antibiotic therapy courses or invasion of P. aeruginosa into the CF airways (Klepac-Ceraj et al., 2010). Microevolution processes have been studied most widely in P. aeruginosa.

Pseudomonas aeruginosa is the most prevalent pathogen

The capacity of P. aeruginosa to cause infections in CF patients and other hosts can be traced back to its considerable adaptability to specific environmental conditions and the production of numerous virulence factors (Lee et al., 2006) (see Box 1). This adaptability is linked to a large number of regulatory genes. For example, in the 6.3 Mb genome of P. aeruginosa PAO1, which contains 5570 predicted ORFs, 521 known or putative regulatory genes have been identified, demonstrating a highly complex gene regulation (Stover et al., 2000). The P. aeruginosa chromosome contains a core genome consisting of the sequences that are common to all strains of the taxon and variable amounts of accessory DNA segments. The accessory genome that can be horizontally transferred among strains represents the flexible gene pool that frequently undergoes acquisition and loss of genetic information and hence plays an important role in the adaptive evolution of bacteria. The flexible gene pool is made up of elements such as bacteriophages, plasmids, insertion elements, transposons, conjugative transposons, integrons and genomic islands. Isolates from CF patients and environment are endowed with a variable repertoire of genomic islands (Klockgether et al., 2007; Wiehlmann et al., 2007). The genes required for pathogenicity in one strain of P. aeruginosa are neither required for nor predictive of virulence in other strains (Lee et al., 2006; Bragonzi et al., 2009), indicating a broad intraclonal diversity of pathogenicity of this organism, yet no difference in virulence. Despite the high overall genome similarity of P. aeruginosa of <0.5% sequence diversity in the core genome, comprising 80% of all genes, differences in phenotypes can be striking even at the intraclonal level of genetically highly related strains (Wehmhöner et al., 2003; Salunkhe et al., 2005a, b).

Table Box 1..   Virulence factors of Pseudomonas aeruginosa and their regulation by quorum sensing
Pseudomonas aeruginosa produces many virulence factors, which can be divided into cell-associated and extracellular virulence factors. Many virulence factors are regulated by the quorum-sensing circuit and other regulatory genes, which have been demonstrated in vitro and in vivo. During the chronic course of lung infections in patients with CF, many mutants have been characterized that are defective in virulence factor expression and quorum sensing (D'Argenio, 2004; Hogardt et al., 2004, 2007; van Delden, 2004; Ramsey & Wozniak, 2005; Lee et al., 2006; Williams & Camara, 2009; Winstanley & Fothergill, 2009). Cell-associated virulence factors Flagella, type IV pili, lipopolysaccharide and three different exopolysaccharides, encoded by the alg, psl and pel clusters, contribute to adhesion of the microorganism to various surfaces. On epithelial cells, flagellar proteins bind to toll-like receptor (TLR)-5 and lipopolysaccharide to TLR-4, leading to the stimulation of innate immune functions and inflammation. The exopolysaccharides have been implicated in biofilm formation. Flagella, lipopolysaccharide and alginate antibodies have been detected in the sera of infected CF patients. Extracellular virulence factors Type I, II and III secretion systems secrete protein toxins and provide contact with eukaryotic cells. Alkaline protease is secreted by the type I secretion system, while the LasB and LasA elastases, protease IV, exotoxin A, phospholipase C and lipase are secreted by the type II secretion system. The type III secretion system injects the exoenzymes S, T, Y and U into eukaryotic cells. Other extracellular virulence factors include the secondary metabolites pyocyanin and other phenazine pigments, siderophores, hydrogen cyanide and rhamnolipids. Most exoenzymes and secondary metabolites have been shown to be cytotoxic in in vitro and in animal models, and antibodies to many of these factors have been detected in the sera of infected CF patients. Quorum-sensing circuit Several virulence factors are regulated in a cell-density-dependent manner by the quorum sensing circuit composed of lasRI, rhlRI and pqs systems. Pseudomonas aeruginosa produces several diffusible signal molecules with autoinducer properties such as N-3-oxo-dodecanoyl homoserine lactone (produced by the LasI enzyme) and N-butanoyl homoserine lactone (produced by theRhlI enzyme), which bind at critical concentrations to the corresponding regulators LasR and RhlR. The lasRI system mainly regulates lasB, lasA, exoA, xcpP and xcpR expression. The rhlRI system regulates the expression of rpoS, rhamnolipid, LasB and LasA elastase, hydrogen cyanide, pyocyanin, lipase and alkaline protease. The Pseudomonas quinolone signal system potentiates the effects of the rhlRI system. Quorum sensing controls not only virulence in P. aeruginosa but also many other genes involved in cellular processes, including chemotaxis and biofilm formation, comprising altogether about 10% of the P. aeruginosa genome. In addition, quorum-sensing molecules also modulate host responses.

Various morphotypes that are not normally present in environmental P. aeruginosa strains have been described in P. aeruginosa strains, isolated from chronically infected CF patients, including strains that are mucoid, smooth, rough, dwarf, colourless or present as small colony variants (SCV) (size: 1–3 mm). The latter may contribute to the progressive pulmonary damage in CF and persistence in CF airways (Häussler et al., 1999, 2003; Lory et al., 2009; Starkey et al., 2009). Additionally, ‘rugose SCVs’ have been detected that have characteristics of enhanced biofilm formation and display increased expression of the pel and psl polysaccharide gene clusters, decreased expression of motility functions and a defect in growth on some amino acid and tricarboxylic acid cycle intermediates as sole carbon sources (Starkey et al., 2009). The psl (polysaccharide synthesis locus) genes are responsible for the production of mannose-rich exopolysaccharides and the pel locus for pellicle formation.

A consistent finding in CF airways is the presence of mucoid P. aeruginosa strains that overproduce the exopolysaccharide alginate, a negatively charged polymer of β-1-4-linked d-mannuronate, and its C5 epimer, l-guluronate (Deretic et al., 1995; Boucher et al., 1997). Alginate expression is upregulated by microaerobic environmental conditions that are present in the viscous mucus of CF patients (Worlitzsch et al., 2002). Alginate expression is considered to be an important factor for the persistence of P. aeruginosa in the airways of CF patients as alginate protects the pathogen not only against innate immune functions but also against opsonophagocytosis involving specific antibodies, produced by the adaptive immune system. A key element in alginate regulation is the alternative sigma factor AlgT, also known as AlgU, RpoE or σ22, which induces the expression of algD and increases the expression of regulatory proteins that enhance algD transcription (Ramsey & Wozniak, 2005). The anti-sigma factor MucA inhibits AlgT; thus, inactivation of mucA leads to upregulation of AlgT and conversion to mucoidy. Overproduction of alginate has been linked to biofilm formation in P. aeruginosa– a phenotype that favours chronic persistence of the pathogen in murine and CF lungs (Hoffmann et al., 2005). However, both mucoid and nonmucoid P. aeruginosa clonal strains occur in the airways of CF patients simultaneously (Bragonzi et al., 2009). Furthermore, the finding that a high number of nonmucoid strains from CF patients carry a mucA mutation (Bragonzi et al., 2006) suggests that a mucoid morphotype, intermittently selected in the CF lungs, can be suppressed at a later stage due to other, secondary site mutations (Boles et al., 2004), including mutations in algU (Ciofu et al., 2008). Interestingly, P. aeruginosa rpoS mutants reveal a significantly reduced production of alginate (Suh et al., 1999). Mucoid P. aeruginosa strains from CF patients also contain increased levels of G6PDH activity and expression of the corresponding zwf gene. This allows the bacterium to supply sufficient amounts of precursor for the alginate pathway (Silo-Suh et al., 2005).

Other phenotypic changes of P. aeruginosa strains occurring during the course of chronic CF lung infection include loss of motility (Luzar et al., 1985; Rau et al., 2010), decreased exotoxin A expression (Suh et al., 1999), loss of O antigen in lipopolysaccharide (Hancock et al., 1983) and altered lipid moieties (Ernst et al., 1999; Sabra et al., 2003). The latter change confers enhanced resistance to aminoglycoside antibiotics, cationic antimicrobials such as polymyxin E (colistin) and potentially to cationic peptides produced by the host (defensins). Mutations in nfxB, the repressor of the MexCD-OprJ operon, results in increased resistance to fluoroquinolones (Rau et al., 2010). Furthermore, increased auxotrophy (Taylor et al., 1993; Thomas et al., 2000), defects in type II (Woods et al., 1986) and III secretion (Jain et al., 2004; Lee et al., 2005; Hogardt et al., 2007; Rau et al., 2010), reduced production of proteases and phospholipase C, loss of pyoverdine, pyocins and elastase expression (Hogardt et al., 2007), altered metabolic activities (Silo-Suh et al., 2005) and antibiotic resistance (Thomassen et al., 1979; Oliver et al., 2000; Smith et al., 2006; Hogardt et al., 2007) have been described in P. aeruginosa strains from CF patients. Particularly during acute exacerbations, methionine-dependent auxotrophic mutants of P. aeruginosa have been isolated from CF patients (Taylor et al., 1993). In conclusion, chronic exposure to the CF environment selects for a variety of mutations in P. aeruginosa strains.

The frequency of mutations is increased in hypermutable or mutator strains that reveal defects in genes involved in the DNA repair or error avoidance systems, particularly in the methyl-directed mismatch repair system (Oliver et al., 2002; Ciofu et al., 2005, 2010; Hogardt et al., 2007; Montanari et al., 2007). The percentage of CF patients (60%) carrying at least one hypermutable strain is remarkably high (Montanari et al., 2007). Analysis of the genetic background of the P. aeruginosa mutator phenotypes from CF airways showed that mutS was the most commonly affected gene, followed by mutL (Ciofu et al., 2010). A sequential analysis of CF isolates revealed that mutations in mucA, leading to the mucoid phenotype and lasR, leading to loss of quorum sensing (Box 1), occurred earlier than mutations in the mut genes, showing that hypermutability is not a prerequisite for the acquisition of mucoidy and loss of quorum sensing (Ciofu et al., 2010). Accumulation of mutators in the CF lung is associated especially with multidrug resistance development, thus suggesting that the intensive antibiotic treatment is one of the main selective pressures for the maintenance and amplification of mutators (Oliver et al., 2000; Ciofu et al., 2010). The acquisition of a stable mutator phenotype may confer a selective advantage for bacteria, particularly in stressful and/or fluctuating environments because this may increase the probability of generation of adaptive variants (Taddei et al., 1997).

The genetic analysis of clonal isolates, obtained from the CF lung of single patients over several years, revealed the presence of mutations in many genes (Mahenthiralingam et al., 1994; Anthony et al., 2002; Nguyen & Singh, 2006; Smith et al., 2006; Tümmler, 2006; Hogardt et al., 2007; Hoboth et al., 2009; Mandsberg et al., 2009; Ciofu et al., 2010; Rau et al., 2010). When a P. aeruginosa isolate was compared with its clonal variants, isolated 90 months later from a single CF patient, revealing 68 mutations, the analysis suggested a reduced virulence of the latter strains with regard to their ability to induce acute infections, based on mutations in many virulence genes including type III secretion, quorum sensing and motility (Smith et al., 2006) (Table 1). The progressive microevolution of P. aeruginosa in CF patients, known as adaptive radiation, has been interpreted as an in vivo selection process, resulting in less virulent variants that consequently do less harm to their host than the original colonizing strain (Smith et al., 2006).

Table 1.   Gene mutations present in Pseudomonas aeruginosa cystic fibrosis isolates
mexZPA2020*Transcriptional regulator of multidrug efflux1
lasRPA1430Transcriptional regulator of quorum sensing1
PA0313Probable permease of the ABC transporter1
mexAPA0425RND multidrug efflux membrane fusion protein1
accCPA4848Biotin carboxylase1
vfrPA0652Transcriptional regulator of lasR1
mexSPA2491Probable oxidoreductase1
exsAPA1713Transcriptional regulator of type III secretion1
PA0506Probable acyl-CoA dehydrogenase1
wspFPA3703Probable methylesterase involved in chemosensory signal transduction1
rpoNPA4462RNA polymerase σ-54 factor1
fleQPA1097Transcriptional regulator of flagella synthesis1
mexTPA2492Transcriptional regulator of multidrug efflux1
nalDPA3574Probable transcriptional regulator1
ampDPA4522β-Lactamase expression regulator1
PA0366Probable aldehyde dehydrogenase1
cyaBPA3217Adenylate cyclase1
pilBPA4526Type 4 fimbrial biogenesis protein1
PA1333Hypothetical protein1
PA3565Probable transcriptional regulator1
PA2312Probable transcriptional regulator1
anrPA1544Transcriptional regulator of anaerobic metabolism1
rhlRPA3477Transcriptional regulator of quorum sensing1
phoPPA1179Two-component response regulator1
rhlIPA3476Autoinducer synthesis protein1
PA4796Hypothetical protein1
pqsBPA0997Homologous to β-keto-acyl-acyl carrier1
 protein synthase1
toxRPA0707Transcriptional regulator1
PA2435Probable cation-transporting P-type ATPase1
PA4420Hypothetical protein1
PA2121Hypothetical protein1
mutSPA3620DNA mismatch repair protein MutS2–4
mutLPA4946DNA mismatch repair protein MutL3, 4
mutYPA5147A/G specific adenine glycosylase4, 5
uvrDPA5443DNA helicase II3, 4
mucAPA0763Anti-sigma factor MucA4, 6
nfxBPA4600Transcriptional regulator7

Although this notion may actually be correct, the definition of virulence also includes the capacity of the pathogen to persist in a given host, causing chronic infection. To test this hypothesis, Bragonzi et al. (2009) isolated P. aeruginosa clones from airways of six CF patients during a period of up to 16.3 years and assessed the virulence of clonal variants in mice by monitoring acute and chronic lung infection. Because the definition of virulence is also dependent on a specific host, they tested the clonal variants in mice with different genetic backgrounds, including CF mice. The data demonstrate that early and intermediate P. aeruginosa CF isolates are more virulent to cause acute infections (e.g. bacteraemia) in mouse lungs than late isolates; however, early, intermediate and late isolates do not differ in their capacity to cause chronic infection (Fig. 3). These findings suggest that clonal expansion of P. aeruginosa strains during microevolution within CF lungs leads to populations with altered, but not reduced virulence in mouse lung models. Thus, it may be questionable to define late isolates as less virulent than early isolates or to describe the pathogenicity of CF lung disease as a process leading to an increasingly benign situation. However, the animal experiments used to determine virulence do not reflect a natural colonization process with initially small numbers of bacteria.


Figure 3.  Virulence of Pseudomonas aeruginosa strains in a murine model of airways infection. C57Bl/6NCrlBR mice were infected with 1–2 × 106 CFU per lung of 32 P. aeruginosa different strains embedded in agar beads. Mortality induced by bacteraemia (red) and survival (grey) were evaluated on challenged mice. Clearance (white) and capacity to establish chronic airways infection (green) after 14 days from challenge were determined on surviving mice. The data show the percentage of mice infected with P. aeruginosa reference strains (PAO1, n=66; PA14, n=14), a pool of environmental strains (n=65) and a pool of clinical strains (n=274), isolated at the onset (n=91), during the intermediate phase of colonization (n=65) or later during chronic infection (n=118) (adapted from Bragonzi et al., 2009).

Download figure to PowerPoint

Pseudomonas aeruginosa proteins are upregulated in the CF lung, including the outer membrane protein OprF and enzymes of the arginine deiminase pathway (Hoboth et al., 2009) (Table 2). These changes indicate an adaptive shift towards constitutive expression of genes required for growth under the nutritional and microaerobic conditions present in the sputum of CF patients. The high viscosity of the CF mucus also leads to a limited diffusion of siderophore molecules and therefore to an increased fitness of siderophore-producing cells (Cornelis et al., 2009; Kummerli et al., 2009).

Table 2.   Metabolic adaptation of Pseudomonas aeruginosa strains during chronic lung infection in cystic fibrosis patients based on protein expression*
  • *

    Adapted from Hoboth et al. (2009).

  • Genes whose expression tends to be strongly upregulated during late chronic infection.

rbsBPA1946Binding protein RbsB of ABC ribose transporter
aotJPA0888Arginine-ornithine-binding protein
PA5153Probable lysine-arginine-ornithine-binding periplasmic protein
PA1260Probable lysine-arginine-ornithine-binding periplasmic protein
braCPA1074Periplasmic branched-chain amino acid transport protein
spuDPA0300Polyamine transport protein
oprFPA1777Outer membrane porin OprF
oprDPA0958Outer membrane porin OprD
fdaPA0555Fuctose-1,6-bisphosphate aldolase
adkPA3686Adenylate kinase
azuPA4922Azurin precursor
ccpRPA4587Cytochrome c551 peroxidase precursor
leuDPA31203-Isopropylmalate dehydratase small subunit
hisF1PA5140Imidazoleglycerol-phosphate synthase, cyclase subunit
arcAPA5171Arginine deiminase
arcCPA5173Carbamate kinase
PA2888Probable biotin-dependent carboxylase
acpPPA2966Acyl carrier protein
accBPA4847Acetyl-CoA carboxylase
ppaPA4031Inorganic pyrophosphatase
sucCPA1588Succinyl-CoA synthetase (b-chain)
lpd3PA4829Dihydrolipoamid dehydrogenase 3
aceBPA0482Malate synthase G (glyoxylate shunt)
atpFPA5558ATP synthase B chain
atpHPA5557ATP synthase H chain
pdxHPA1049Pyridoxamin 5-phosphate oxidase
glnKPA5288Nitrogen-regulatory protein P-II 2
atoDPA1999Probable CoA-transferase, subunit A
atoBPA2001Acetyl-CoA acetyltransferase
PA0318Hypothetical protein
PA2575Hypothetical protein
PA0388Hypothetical protein
PA3440Hypothetical protein
PA1677Hypothetical protein
PA5178Hypothetical protein
PA3309Hypothetical protein
PA5339Hypothetical protein
btuEPA0838Glutathione peroxidase
sodBPA4366Superoxide dismutase
kynBPA2081Kynurenine formamidase
bfrAPA4235Bacterioferritin A
ahpCPA0139Alkyl hydroperoxide reductase subunit C
tsaAPA3529Probable peroxidase
ibpAPA3126Heat-shock protein IbpA
ppiBPA1793Peptidyl-prolyl cis-trans isomerase B
rpsFPA493530S ribosomal protein S6
PA4671Probable ribosomal protein L25
greAPA4755Transcription elongation factor GreA
rplLPA427150S ribosomal protein L7/L12
tsfPA3655Elongation factor
tufAPA4265Elongation factor Tu
guaBPA3770Inosine-5′-monophosphate dehydrogenase
pilHPA0409Twitching motility protein PilH
fliCPA1092Flagellin type B
murFPA4416UDP-N-acetylmuramoylalanyl-d-glutamyl-2,6-diaminopimelate-d-alanyl-d-alanyl ligase
ftsZPA4407Cell division protein FtsZ

Other bacterial pathogens in CF

Staphylococcus aureus also changes its phenotype under microaerobic/anaerobic environmental conditions in vitro and in the CF mucus, forming biofilm-like aggregates (McKenney et al., 1999; Cramton et al., 2001; Ulrich et al., 2007), which differ genotypically and phenotypically from environmental strains and strains from the nasal habitat (Goerke & Wolz, 2004). The exopolysaccharide present in S. aureus biofilms (Cramton et al., 1999), initially named polysaccharide intracellular adhesin and later poly-N-acetyl glucosamine (PNAG), differs structurally from the S. aureus capsule polysaccharides, which are lost during growth in the CF airways due to elevated pCO2 (∼4%) (Herbert et al., 1997). The PNAG-encased cells confer resistance to nonoxidative killing (Ulrich et al., 2007). Phage mobilization, possibly via transduction, contributes significantly to genome alteration in S. aureus during infection in CF patients (Goerke et al., 2004), and agr mutants are frequently isolated from these specimens (Goerke et al., 2000). Agr (for accessory gene regulator) is a well-characterized global regulatory locus that is expressed from two promoters: P2 and P3 (Novick et al., 1993, 1995). Agr regulates staphylococcal virulence and other accessory gene functions, including the expression of haemolysins. While the P2 RNAII transcript codes for the quorum-sensing elements AgrA, AgrC, AgrB and AgrD, P3 activation, during the late exponential growth phase, leads to the transcription of RNAIII, resulting in the repression of surface proteins such as adhesins or protein A and in the enhanced expression of exoproteins such as haemolysins (Novick, 2003). Agr mutants show enhanced biofilm formation in S. aureus, as Agr activation results in the expression of extracellular proteases (Boles & Horswill, 2008) and membrane-active molecules (Kong et al., 2006), such as the δ-toxin, which contribute to the dispersal of biofilms.

Often SCVs of S. aureus, which may persist in respiratory epithelial cells, are detected in CF lung specimens (Sadowska et al., 2002; von Eiff, 2008). SCVs are mostly nonpigmented and nonhaemolytic and their colonies are ∼10 times smaller than those of the parental strain. In general, SCVs are auxotrophic for haemin and menadione, compounds involved in the biosynthesis of electron transport chain components. Most SCVs of S. aureus, isolated from CF patients, are thymidine-auxotrophic due to long-term trimethoprim-sulphomethoxazol treatment (Schneider et al., 2008). Treatment of CF lung infections using the aminoglycoside tobramycin may result in local subinhibitory concentrations that favour the emergence of aminoglycoside-resistant SCVs (Mitchell et al., 2010), involving the global regulator SigB (Biswas et al., 2009). Besides antibiotics, coinfecting P. aeruginosa can also promote the formation of S. aureus SCVs by producing respiration inhibitors such as 4-hydroxy-2-heptylquinoline-N-oxide (Hoffman et al., 2006; Biswas et al., 2009). Molecular characterization of SCVs from CF patients also revealed that they may be defective in the expression of the agr system (Novick et al., 1993). Taken together, the adaptation of S. aureus to the CF lung leads to biofilm formation and SCVs, both of which favour chronic infection states as a result of increased resistance to innate immune defence mechanisms and antibiotic treatment. Without optimized anti-staphylococcal treatment strategies that reduce the bacterial load in the airways (Döring et al., 2004), chronic S. aureus lung infections may be considerably harmful for the CF patient. Indeed, before the introduction of anti-staphylococcal agents, virtually all CF patients were infected with this opportunistic pathogen (Andersen, 1938), which was held responsible for the widespread pulmonary changes in CF (di Sant'Agnese & Talamo, 1967).

The Bcc is a group of genetically distinct, but phenotypically similar bacteria that are divided into at least nine species (Coenye et al., 2001). All group members can cause infections in CF patients, albeit with a low prevalence (∼2–3%). Bcc strains are extremely sensitive towards ROS; this is reflected by the minimal mortality of neutropenic mice when infected with this opportunistic pathogen (Chu et al., 2002). However, in sputum plugs in airways of CF patients where ROS are essentially absent due to the anaerobic/microaerobic environment and in patients with the hereditary disorder chronic granulomatous disease (CGD) who suffer from mutations in NADPH oxidase, this opportunistic pathogen is highly virulent due to its intrinsic resistance to nonoxidative killing during phagocytosis by professional phagocytes (Speert et al., 1994; Pollock et al., 1995; Baird et al., 1999; Sahly et al., 2003; Segal et al., 2003; Sousa et al., 2007). Resistance to cationic antimicrobial peptides (CAMPs) has been linked to the presence of 4-amino-4-deoxyarabinose moieties, which are attached to the phosphate residues in the lipid A backbone of Bcc lipopolysaccharides (Cox & Wilkinson, 1991; Vinion-Dubiel & Goldberg, 2003).

While some strains may cause long-term asymptomatic airway colonization, others cause a rapid decline of lung function in CF patients and are highly transmissible, resulting in patient-to-patient spread within and between CF centres (Govan et al., 1993; Mahenthiralingam et al., 2005). For instance, Burkholderia cenocepacia strains of the multilocus enzyme electrophoresis type 12 lineage can cause a fulminate, necrotizing pneumonia, which may occasionally be complicated by rapidly fatal septicaemia termed the cepacia syndrome in CF patients (Corey & Farewell, 1996; Jones et al., 2001).

As with other opportunistic pathogens, Bcc virulence in CF and CGD patients is multifactorial (for a comprehensive review of Bcc virulence factors, see Mahenthiralingam et al., 2005). Besides lipopolysaccharides, which cause significantly more inflammation than does P. aeruginosa lipooligosaccharides (Mahenthiralingam et al., 2005), biofilm formation has been implicated to play a role in the pathophysiology of CF lung disease (Mahenthiralingam et al., 2005). Many Bcc strains can produce biofilms in vitro (Ferreira et al., 2010), associated with the ability to produce N-acyl-homoserine lactones (Conway et al., 2002), which may protect single cells from antibiotic killing (Desai et al., 1998). Also, the ability of Bcc strains to form mixed biofilms with P. aeruginosa has been demonstrated (Riedel et al., 2001). In a CGD mouse model of Bcc lung infection (Sousa et al., 2007), survival and death of the infected animals was correlated to the growth rate of the different Bcc strains. The highest growth rate was found for the epidemic strain J2315, which multiplied from 103 CFU–108 CFU within 3 days, whereas for example a Burkholderia vietnamensis strain never killed any mouse and reached only ∼104 CFU after 12 days of infection. Thus, genes active in metabolism may be important for Bcc virulence in CF and CGD. Whether Bcc strains adapt genotypically or phenotypically to the CF niche is not known.

As in P. aeruginosa, hypermutable phenotypes have been observed repeatedly in S. aureus (Prunier et al., 2003), H. influenzae (Roman et al., 2004; Watson et al., 2004) and Bcc strains from CF patients (Burns, 2005), suggesting that this mechanism may play a crucial role in the pathogenesis of chronic lung infection.

Bacteria colonization in COPD

  1. Top of page
  2. Abstract
  3. Introduction
  4. Pathophysiology of CF lung disease
  5. Pathophysiology of COPD
  6. Bacterial colonization of the CF lung
  7. Bacteria colonization in COPD
  8. Antimicrobial treatment for CF patients
  9. Antimicrobial treatment for COPD patients
  10. Concluding remarks
  11. Acknowledgements
  12. References

In contrast to CF, the role of pathogenic bacteria in the progression of COPD is an area of uncertainty and the subject of active research. Opportunistic pathogenic bacteria including NTHI, M. catarrhalis, S. pneumoniae and P. aeruginosa are detectable in airways of approximately 25–50% of clinically stable COPD patients (Sethi & Murphy, 2008). Pathogenic bacteria in the lower airways induce increased airway inflammation, a hallmark of COPD, even in the absence of symptoms of acute exacerbation (Soler et al., 1999; Hill et al., 2000), supporting the ‘vicious circle’ hypothesis that proposes that persistent bacterial infections cause progressive lung damage in COPD. This notion is further substantiated by the finding that the frequency of positive cultures increases in patients with more severe COPD (Eller et al., 1998). Thus, chronic bacterial and/or viral infections may play a role in the development and progression of COPD (Sethi & Murphy, 2008). However, conclusive evidence for this hypothesis is lacking at present. A key question on which research effort should be focused is whether or not chronic infection of the airways in COPD accelerates the progressive loss of lung function. Understanding the role of chronic infection in the course of the disease would serve as an important guide in directing research in the field. For example, if chronic infection were shown to cause increased progression of the disease, then the priority should be to develop methods such as vaccines or immunomodulators to eradicate chronic colonization.

The causative role of pathogenic microorganisms in acute exacerbations of COPD, however, is well established (Sethi & Murphy, 2008). Opportunistic pathogenic bacteria are responsible for approximately 50% of exacerbations, while virus-induced exacerbations caused by rhinovirus, respiratory syncytial virus, adenovirus, influenza virus and human metapneumovirus (Greenberg et al., 2000; Seemungal et al., 2001) are approximately 30% (Sethi & Murphy, 2008). Coinfections are frequent. Table 3 shows the relative distribution of bacterial pathogens that caused exacerbations in a 10-year prospective study (Murphy & Parameswaran, 2009). Studies of COPD patients using bronchoscopy and protected specimen brush sampling of distal airways, avoiding upper airway contamination, have consistently shown pathogenic bacteria in quantities indicative of infection (Monso et al., 1995; Soler et al., 1999). Moreover, a comparison of exacerbation and stable state patients, using the same technique, showed significantly higher quantities of these bacteria during exacerbation (Fagon et al., 1990; Soler et al., 1998). Longitudinal molecular typing of pathogenic bacteria from sputum cultures showed that acquisition of a new strain was associated with a twofold increase in the incidence of exacerbations (Sethi et al., 2002). Purulent sputum, a marker of exacerbation, is strongly associated with the presence of pathogenic bacteria in sputum (White et al., 2003; Soler et al., 2007).

Table 3.   Relative distribution of bacterial pathogens in COPD
Bacterial speciesPositive culture*Exacerbation
  • *

    Number of positive cultures for the pathogen, isolated from the sputum of adults with COPD, followed in a 10-year prospective study in Buffalo, NY.

  • Number of exacerbations in the same 10-year prospective study as defined by the acquisition of a new bacterial strain (based on molecular typing of cultured isolates) simultaneous with symptoms of exacerbation (adapted from Murphy & Parameswaran, 2009).

Haemophilus influenzae70784
Moraxella catarrhalis31068
Streptococcus pneumoniae21911
Pseudomonas aeruginosa23015

NTHI and M. catarrhalis are prevalent pathogens

Haemophilus influenzae strains may produce antigenically distinct polysaccharide capsules, which distinguishes strain types ‘a’ through ‘f’. In contrast, strains of H. influenzae that colonize and infect the airways in COPD are nonencapsulated as demonstrated by a lack of reactivity with typing sera for each of the six known capsular serotypes. Thus, these strains are referred to as nontypeable, abbreviated NTHI. Haemophilus influenzae strains use several genetic mechanisms that alter either the gene expression or the gene content that allow rapid adaptation and improved fitness to changing environments including phase variation based on slipped-strand mispairing, mediated by short DNA repeats in either the coding regions or the upstream promoter regions of virulence genes (Gilsdorf et al., 2004; Srikhanta et al., 2010). Phase variation results in a large genetic diversity among H. influenzae strains present in different environments, which complicates the interpretation of virulence-related phenotypes. The multifactorial virulence of H. influenzae strains includes factors such as lipooligosaccharides (Schweda et al., 2007), fimbriae encoded by the hif locus, IgA1 protease(s) (Erwin & Smith, 2007) and the ability to form biofilms (Starner et al., 2006).

NTHI strains show a highly variable pattern of carriage among COPD patients. Some strains of NTHI, causing exacerbations, can also persist for longer periods of time than is apparent from sputum cultures. Molecular analysis shows that a strain is present in COPD airways during periods when it cannot be recovered by routine culture, indicating that selected strains persist in the airways for months to years. A 7-year prospective study (Murphy et al., 2004) including 104 COPD patients observed 17 episodes of prolonged (>6 months) periods of negative sputum cultures preceded and followed by genotypically identical strains of NTHI. Clearing and reacquisition of the identical strain by the patients was ruled out, because NTHI strains are genetically highly heterogeneous, making the reacquisition of the same strain circulating in the community a highly unlikely event. Furthermore, H. influenzae does not remain viable on inanimate objects in the environment even for minutes. Finally, analysis of sputum samples yielding negative cultures revealed the presence of strain-specific NTHI genes, further establishing persistent colonization in COPD patients. Newly acquired NTHI strains isolated from COPD patients during exacerbations, when compared with persisting strains, induce more airway inflammation, including neutrophil influx and IL-8 secretion from respiratory epithelial cells, and adhere more efficiently to the epithelial cells in vitro (Chin et al., 2005). These data suggest that, as with P. aeruginosa in chronic CF lung infection, adaptive processes may occur that modulate the virulence of this pathogen. However, similar molecular studies as mentioned above for P. aeruginosa (Smith et al., 2006; Bragonzi et al., 2009) have not yet been carried out for sequential NTHI isolates from single COPD patients to substantiate this notion. Analysis of the genome content of strains of NTHI that persist in the airways of COPD patients in comparison with those that are cleared quickly will help elucidate the relative roles of the host and pathogen in the dynamics of infection in COPD airways.

Also, M. catarrhalis is regarded as an important human mucosal pathogen in COPD patients (de Vries et al., 2009; Murphy & Parameswaran, 2009). Virulence factors include a family of ubiquitous surface proteins, including the ubiquitous surface protein A1 (UspA1) and UspA2, which can bind α1-antichymotrypsin, thereby potentially increasing the protease activity in vivo, which may cause excessive inflammation in COPD patients (Perez Vidakovics & Riesbeck, 2009). In contrast, UspA1 has been shown to bind to the human-specific extracellular immunoglobulin V (IgV)-like amino-terminal domain of carcinoembryonic antigen-related cell adhesion molecule 1, resulting in reduced toll-like receptor 2-initiated transcription factor nuclear factor-κB-dependent inflammation (Slevogt et al., 2008). Which of these mechanisms dominate during M. catarrhalis infection in COPD patients is unclear.

COPD patients who acquire new strains of M. catarrhalis usually clear this species efficiently from their airways in approximately 1 month. In a study including 104 COPD patients who experienced 560 exacerbations, molecular typing identified 120 episodes of acquisition and clearance of M. catarrhalis in 50 patients (Murphy et al., 2005). Reacquisition of the same strain was rare. The rapid establishment of protective antibody responses against the pathogen in these patients suggested that the clearance of M. catarrhalis is a function of a functional immune system (Murphy et al., 2005). The findings that 57 (47.5%) of M. catarrhalis acquisitions were associated with clinical exacerbations (Murphy et al., 2005), and that increased inflammation and tilting of the protease–antiprotease balance in favour of protease activity occurred in airways of COPD patients during exacerbation as well as colonization with M. catarrhalis (Parameswaran et al., 2009), suggest that this pathogen contributes to the long-term decrease of lung function in COPD patients. Calculations revealed that M. catarrhalis likely causes ∼10% of exacerbations of COPD.

Pseudomonas aeruginosa does not commonly show persistence in COPD

In a chronic lung disease such as COPD, which is characterized by chronic inflammation, progressive tissue destruction and increased mucus production, one would expect persisting P. aeruginosa clones undergoing a similar microevolution as described above for the P. aeruginosa strains in CF airways. Indeed, single clones of P. aeruginosa have been identified in COPD patients that persisted over several years and developed an increasing number of mutations during the chronic course of the disease, resulting in reduced motility, decreased protease production and increased antibiotic resistance as also recognized in patients with CF (Martinez-Solano et al., 2008). Furthermore, different morphotypes of P. aeruginosa, including SCVs and mucoid phenotypes, were observed in sputum isolates from a single COPD patient, suggesting that in this disease diversification also plays an important role in bacterial persistence. Additionally, strains that persisted over long periods of time tended to be hypermutable as in CF (Martinez-Solano et al., 2008).

However, the similarity to CF reduces when larger patient groups are investigated longitudinally. In a 10-year study involving 126 COPD patients, only 13 strains persisted for >6 months and only four of these were mucoid (Murphy et al., 2008). These data suggest that most COPD patients had sporadic and intermittent infection of airways with P. aeruginosa, which were repeatedly cleared. Strains from one clone were generally cleared by the patients' immune system and a gap in time existed before the acquisition of a strain from a different clone (Rakhimova et al., 2009). Chronic carriage of a clone was observed in a minority of investigated patients in this study. When a clone chronically persisted in COPD-affected lungs for an extended period of time, the clone often altered the repertoire of its accessory genome. Hence, intraclonal microevolution and the frequent turnover or loss of clones are typical of infections with P. aeruginosa in COPD. This epidemiological signature is divergent from that of the chronic P. aeruginosa infections in patients with CF, the latter being characterized by no or slow turnover of clones (Rakhimova et al., 2009).

Circumstantial evidence suggests that chronic infection of COPD airways by P. aeruginosa occurs in those with more severe COPD, particularly among patients who require mechanical ventilation for severe exacerbations (Miravitlles et al., 1999; Ferrer et al., 2005; Rosell et al., 2005; Nseir et al., 2006), or in other words, patients with more severe reduction in FEV1, when compared with those with milder disease, are more likely to harbour P. aeruginosa in their lower airways (Eller et al., 1998). Patients with more severe COPD also experience a higher number of acute exacerbations and there is increasing recognition that P aeruginosa is responsible for such exacerbations (Murphy et al., 2008). Whether chronic P aeruginosa infection has a negative impact on lung function and the patients' prognosis requires further study.

The role of P. aeruginosa in the clinical evolution of COPD is not well understood. Unlike in CF, no clear evidence of worsening of lung infection and increased mortality is correlated to chronic P. aeruginosa infection in COPD. Furthermore, unlike in CF, eradication of colonizing pathogenic bacteria, in the absence of exacerbation symptoms, has not been shown to be beneficial in the clinical course of COPD. The questions as to why only some patients develop these chronic infections and why only selected bacterial pathogens establish these infections in COPD remain unanswered at present. Multiple host factors including the severity of COPD, genetic polymorphisms as well as bacterial virulence factors in specific clones may play a role in this context. However, a comparison of P. aeruginosa clones in the airways of patients with COPD with those in the airways of chronically infected patients with CF revealed that despite the disparate geographic origin of the isolates, the dominant P. aeruginosa clones were found with similar frequencies in acutely and chronically infected respiratory tracts irrespective of the aetiology of the disease (Rakhimova et al., 2009) (Fig. 4).


Figure 4.  Distribution of Pseudomonas aeruginosa strains isolated from patients with CF and COPD. (a) Venn diagram of the number of P. aeruginosa clonal complexes obtained from the airways of patients with COPD and CF, respectively. Clonal complexes were calculated from the 15-marker genotype of the core genome using the program eburst (Maiden, 2006). The intersections represent the clonal complexes that had been identified in both diseases. (b) Clonal complex structure of P. aeruginosa strains collected from various different habitats and geographic origins. The eburst analysis was carried out with the informative SNPs of a microassay of the core genome. Coloured clonal complexes contain airway isolates from patients with COPD (yellow), from patients with CF (blue) and from both patient groups (green). The size of the symbol indicates the number of typed strains with an identical genotype. Clones C and PA14 are the most abundant clones (Wiehlmann et al., 2007). Genotypes only observed in other habitats are depicted in grey. (Figure adapted from Rakhimova et al., 2009.)

Download figure to PowerPoint

Antimicrobial treatment for CF patients

  1. Top of page
  2. Abstract
  3. Introduction
  4. Pathophysiology of CF lung disease
  5. Pathophysiology of COPD
  6. Bacterial colonization of the CF lung
  7. Bacteria colonization in COPD
  8. Antimicrobial treatment for CF patients
  9. Antimicrobial treatment for COPD patients
  10. Concluding remarks
  11. Acknowledgements
  12. References

For chronic P. aeruginosa lung infection in CF patients, antibiotic therapy has been a cornerstone, allowing a largely improved life expectancy of the affected patients due to stabilization of lung function; by contrast, lung function rapidly decreases in untreated CF patients. Commonly applied antibiotics include the aminoglycoside tobramycin, the β-lactam antibiotic ceftazidime, the fluoroquinolone ciprofloxacine and the polymyxin E colistin (Döring et al., 2000, 2004). However, this therapy regimen, even when applied as recommended (Döring et al., 2000, 2004), i.e., aggressively every 3 months with high doses of inhaled antibiotics, does not eradicate the chronically persisting P. aeruginosa from the airways of CF patients. The highly viscous mucus plugs and the biofilm-like macrocolonies of P. aeruginosa within these plugs, which impede the penetration of antibiotics, are assumed to be responsible for this negative outcome (Xu et al., 1998; Wimpenny et al., 2000; Worlitzsch et al., 2002; Döring et al., 2004). As mentioned above, the stressful environment in the CF lung also favours the emergence of hypermutable (or mutator) strains of P. aeruginosa, which are deficient in the DNA mismatch repair system. Mutator strains produce antibiotic-resistant mutants at elevated rates (Oliver et al., 2000; Hogardt et al., 2007). Combination therapy using antibiotics having different modes of action against P. aeruginosa could be superior to monotherapy in this situation. Recently, the combination of the fluoroquinolone ciprofloxacin and the amphipathic oligopeptide polymyxin E (colistin) has yielded promising results in killing P. aeruginosa biofilms in vitro, based on the concept of combining antibiotics that have different targets in the biofilm cells. While biofilm cells exhibiting low metabolic activity were killed by colistin, ciprofloxacin was found to specifically kill the subpopulation of metabolically active biofilm cells (Pamp et al., 2008). Whether this strategy is successful in CF patients still needs to be tested.

To avoid the development of resistance and in an attempt to eradicate P. aeruginosa early, CF patients were treated with antibiotics immediately after the first detection of the pathogen. In this case, reported eradication rates were above 95% (reviewed in Döring et al., 2000, 2004).

In addition to antibiotic therapy, other treatment strategies may also be successfully used in CF patients to fight bacterial lung infection. Based on the abnormal accumulation of ceramide in CF airways, leading to DNA deposits on the respiratory epithelium, the sphingomyelinase blocker amitriptyline is currently under investigation in clinical trials (Riethmüller et al., 2009). Furthermore, recombinant human DNAse may be helpful in this context, as evidenced in experimental mouse models of P. aeruginosa lung infection (Teichgräber et al., 2008) and in CF patients with regard to S. aureus (Frederiksen et al., 2006).

An important question is whether antibiotic therapy directed against P. aeruginosa is also effective against the large number of strict anaerobes present in the mucus plugs within the airways of CF patients. Two studies suggest that this is not the case (Tunney et al., 2008; Worlitzsch et al., 2009). If strict anaerobes actually did contribute to lung disease in CF patients, additional antibiotics, specifically active against these pathogens, should be administered to CF patients.

In the case of Bcc infections, there is no doubt that these microorganisms cause lung disease in CF patients. Because of the intrinsic resistance of Bcc strains to many antibiotics, combination therapy with two to three different antibiotics according to minimal inhibition concentration assessment is recommended (Döring et al., 2004).

Antimicrobial treatment for COPD patients

  1. Top of page
  2. Abstract
  3. Introduction
  4. Pathophysiology of CF lung disease
  5. Pathophysiology of COPD
  6. Bacterial colonization of the CF lung
  7. Bacteria colonization in COPD
  8. Antimicrobial treatment for CF patients
  9. Antimicrobial treatment for COPD patients
  10. Concluding remarks
  11. Acknowledgements
  12. References

Antibiotic therapy regimens in COPD have focused on the treatment of exacerbations. However, only approximately 50% of acute exacerbations in COPD patients are caused by bacterial pathogens, a situation that complicates the interpretation of results in such studies. Nevertheless, the data available strongly suggest that antibiotic therapy for acute exacerbations in COPD patients reduces complications and hastens recovery. In a placebo-controlled study, including 173 COPD patients who suffered from 362 acute exacerbations during the study period, the success rate was 68.1% in the antibiotic group vs. 55% in the placebo group (Anthonisen et al., 1987). Most of the success was seen in patients with more severe exacerbations, indicating that patients with more severe exacerbations benefit more from antibiotic therapy. A systematic review analysed 11 placebo-controlled trials (917 patients) of antibiotics in exacerbations of COPD. Combining the data from three trials that used objective definitions of COPD to qualify for inclusion showed a reduction in mortality with antibiotic use and reduction in the rates of treatment failure (Ram et al., 2006). Also, other meta-analyses of placebo-controlled trials revealed a substantial benefit for the antibiotic treatment of acute exacerbations in COPD patients, emphasizing the pathogenic role of bacteria in the course of this disease (Quon et al., 2008; Roede et al., 2009).

Another goal of antimicrobial therapy is to slow or to prevent the worsening of pulmonary function. The use of antibiotics in stable COPD patients to prevent progressive worsening of lung function in the absence of exacerbations has yielded unclear results due to the lack of large studies with stratified COPD patients. Nevertheless, a recent meta-analysis of data from trials conducted in 1950s and 1960s showed that ‘prophylactic antibiotics’ produced a relative risk reduction of 9% for the occurrence of exacerbations (Black et al., 2003). However, even this modest gain should be interpreted with caution because the trials varied markedly in methodology and duration and many of the antibiotics used in these trials would not be expected to be effective with the current susceptibility patterns of bacteria. In a randomized trial, prophylactic erythromycin reduced the frequency of exacerbations in a group of COPD patients and increased the mean interval between exacerbations (Seemungal et al., 2008). Whether the benefits are due to antimicrobial, anti-inflammatory or both effects of erythromycin is not clear. In a recent pilot study involving 13 COPD patients, colonized with multi-drug-resistant P. aeruginosa, inhalation of tobramycin (300 mg twice daily for 2 weeks) reduced the sputum density of P. aeruginosa and the exacerbation rate (Dal Negro et al., 2008). This small uncontrolled study is promising, but needs to be replicated in larger controlled trials that examine the impact of such a treatment on lung function and clinical outcomes.

The success of early treatment with antibiotics in reducing the incidence of airway infection in CF raises the question of whether a similar approach might be effective in adults with COPD, particularly with regard to P. aeruginosa infection. The majority of adults with COPD who acquire P. aeruginosa clear the organism without antibiotic therapy (Murphy et al., 2008). However, patients with more advanced COPD, persistent infection with P. aeruginosa and severe exacerbations are more likely to benefit from antibiotic therapy. Therefore, COPD patients hospitalized with exacerbations, particularly with severe exacerbations revealing purulent sputum masses, and patients with severe underlying COPD having exacerbations should receive antibiotics, according to a decision-making algorithm (Sethi & Murphy, 2008).

It is not known whether the subset of COPD patients who have persistently positive sputum cultures for P. aeruginosa experience adverse consequences of chronic infection, analogous to patients with CF. This is an important question that needs to be addressed in carefully designed clinical trials. The results will have important implications in understanding the pathogenesis of P. aeruginosa infection in COPD and in the clinical management of these patients.

Concluding remarks

  1. Top of page
  2. Abstract
  3. Introduction
  4. Pathophysiology of CF lung disease
  5. Pathophysiology of COPD
  6. Bacterial colonization of the CF lung
  7. Bacteria colonization in COPD
  8. Antimicrobial treatment for CF patients
  9. Antimicrobial treatment for COPD patients
  10. Concluding remarks
  11. Acknowledgements
  12. References

The pathophysiology of CF and COPD lung disease is complex. While chronic pulmonary inflammation triggered by opportunistic pathogens is the cause of the more or less rapidly decreasing lung function in CF, the role of bacterial infection in the pathogenesis of COPD is less well understood. Chronic P. aeruginosa infection plays a critical role in the course of CF, whereas only a small minority of adults with COPD experience chronic P. aeruginosa infection. In COPD, the predominant pathogens are H. influenzae and M. catarrhalis. While in CF airways single P. aeruginosa clones, which adapt genotypically and phenotypically to the CF niche, persist in the majority of patients due to a heavily impaired innate immune system, a frequent turnover and loss of clones are typical of infections with P. aeruginosa in COPD. However, once the extensive tissue remodelling and tissue destruction has reached a certain threshold (which has not yet been determined), opportunistic pathogens such as P. aeruginosa may persist and develop epidemiological signatures similar to those in CF. To prevent this point of no return is a challenge for microbiologists and clinicians.


  1. Top of page
  2. Abstract
  3. Introduction
  4. Pathophysiology of CF lung disease
  5. Pathophysiology of COPD
  6. Bacterial colonization of the CF lung
  7. Bacteria colonization in COPD
  8. Antimicrobial treatment for CF patients
  9. Antimicrobial treatment for COPD patients
  10. Concluding remarks
  11. Acknowledgements
  12. References
  • Andersen DH (1938) Cystic fibrosis of the pancrease and its relation to coelic disease. Am J Dis Child 56: 344399.
  • Anthonisen NR (2002) Bacteria and exacerbations of chronic obstructive pulmonary disease. New Engl J Med 347: 526527.
  • Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK & Nelson NA (1987) Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106: 196204.
  • Anthony M, Rose B, Pegler MB et al. (2002) Genetic analysis of Pseudomonas aeruginosa isolates from the sputa of Australian adult cystic fibrosis patients. J Clin Microbiol 40: 27722778.
  • Baird RM, Brown H, Smith AW & Watson ML (1999) Burkholderia cepacia is resistant to the antimicrobial activity of airway epithelial cells. Immunopharmacol 44: 267272.
  • Barasch J, Kiss B, Prince A, Saiman L, Gruenert D & Al-Awqati Q (1991) Defective acidification of intracellular organelles in CF. Nature 352: 7073.
  • Barnes PJ (2000) Chronic obstructive pulmonary disease. New Engl J Med 343: 269280.
  • Barnes PJ (2004) Alveolar macrophages as orchestrators of COPD. COPD 1: 5970.
  • Barnes PJ, Shapiro SD & Pauwels RA (2003) Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 22: 672688.
  • Berenson CS, Garlipp MA, Grove LJ, Maloney J & Sethi S (2006a) Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease. J Infect Dis 194: 13751384.
  • Berenson CS, Wrona CT, Grove LJ et al. (2006b) Impaired alveolar macrophage response to Haemophilus antigens in chronic obstructive lung disease. Am J Resp Crit Care 174: 3140.
  • Berger M, Sorensen RU, Tosi MF, Dearborn DG & Döring G (1989) Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest 84: 13021313.
  • Biswas L, Biswas R, Schlag M, Bertram R & Gotz F (2009) Small-colony variant selection as a survival strategy for Staphylococcus aureus in the presence of Pseudomonas aeruginosa. Appl Environ Microb 75: 69106912.
  • Bittar F, Riichet H, Dubus J-C et al. (2008) Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. Plos ONE 3: e2908.
  • Black P, Staykova T, Chacko E, Ram FS & Poole P (2003) Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Db Syst Rev 1: CD004105.
  • Boles BR & Horswill AR (2008) Agr-mediated dispersal of Staphylococcus aureus biofilms. PLoS Pathog 4: e1000052.
  • Boles BR, Thoendel M & Singh PK (2004) Self-generated diversity produces ‘insurance effects’ in biofilm communities. P Natl Acad Sci USA 101: 1663016635.
  • Boucher JC, Yu H, Mudd MH & Deretic V (1997) Mucoid Pseudomonas aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection. Infect Immun 65: 38383846.
  • Boucher RC (2007) Airway surface dehydration in CF: pathogenesis and therapy. Annu Rev Med 58: 157170.
  • Bragonzi A, Wiehlmann L, Klockgether J, Cramer N, Worlitzsch D, Döring G & Tümmler B (2006) Sequence diversity of the mucABD locus in Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Microbiology 152: 32613269.
  • Bragonzi A, Paroni M, Nonis A, Cramer N, Montanari A, Rejman J, Di Serio C, Döring G & Tümmler B (2009) Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. Am J Resp Crit Care Dis 180: 138145.
  • Brook I & Fink R (1983) Transtracheal aspiration in pulmonary infection in children with cystic fibrosis. Eur J Respir Dis 64: 5157.
  • Burns JL (2005) Hypermutability in CF pathogens. Pediatr Pulm Suppl 28: 115116.
  • Celli BR & MacNee W (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23: 932946.
  • Chin CL, Manzel LJ, Lehman EE et al. (2005) Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers. Am J Resp Crit Care 172: 8591.
  • Chu KK, Davidson DJ, Halsey TK, Chung JW & Speert DP (2002) Differential persistence among genomovars of the Burkholderia cepacia complex in a murine model of pulmonary infection. Infect Immun 70: 27152720.
  • Ciofu O, Riis B, Pressler T, Poulsen HE & Høiby N (2005) Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob Agents Ch 49: 22762282.
  • Ciofu O, Lee B, Johannesson M, Hermansen NO, Meyer P & Hoiby N for the Scandinavian Cystic Fibrosis Study Consortium (2008) Investigation of the algT operon sequence in mucoid and non-mucoid Pseudomonas aeruginosa isolates from 115 Scandinavian patients with cystic fibrosis and in 88 in vitro non-mucoid revertants. Microbiology 154: 103113.
  • Ciofu O, Mandsberg LF, Bjarnsholt T, Wassermann T & Høiby N (2010) Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants. Microbiology 154: 10031013.
  • Coenye T, Vandamme P, Govan JR & LiPuma JJ (2001) Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol 39: 34273436.
  • Conway BA, Venu V & Speert DP (2002) Biofilm formation and acyl homoserine lactone production in the Burkholderia cepacia complex. J Bacteriol 184: 56785685.
  • Corey M & Farewell V (1996) Determinants of mortality from cystic fibrosis in Canada. Am J Epidemiol 43: 10071017.
  • Cornelis P, Matthijs S & Van Oeffelen L (2009) Iron uptake regulation in Pseudomonas aeruginosa. BioMetals 22: 1522.
  • Cosio MG, Saetta M & Agusti A (2009) Immunologic aspects of chronic obstructive pulmonary disease. New Engl J Med 360: 24452454.
  • Cox AD & Wilkinson SG (1991) Ionizing groups in lipopolysaccharides of Pseudomonas cepacia in relation to antibiotic resistance. Mol Microbiol 5: 641646.
  • Cramton SE, Gerke C, Schnell NF et al. (1999) The intercellular adhesion (ica) locus is present in Staphylococcus aureus and is required for biofilm formation. Infect Immun 67: 54275433.
  • Cramton SE, Ulrich M, Götz F & Döring G (2001) Anaerobic conditions induce expression of the polysaccharide intercellular adhesin in Staphylococcus aureus and Staphylococcus epidermidis. Infect Immun 69: 40794085.
  • Dal Negro R, Micheletto C, Tognella S, Visconti M & Turati C (2008) Tobramycin nebulizer solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation. Adv Ther 25: 10191030.
  • D'Argenio DA (2004) The pathogenic lifestyle of Pseudomonas aeruginosa in model systems of virulence. Pseudomonas: Genomics, Life Style and Molecular Architecture, Vol. 1 (RamosJ-L, ed), pp. 477504. Kluwer Academics/Plenum Publishers, New York.
  • Davies JC (2007) Genotype–phenotype correlations and modifier genes. Cystic Fibrosis (HodsonM, GededsD & BushA, eds), pp. 8186. Hodder Arnold, London.
  • Deretic V, Schurr MJ & Yu H (1995) Pseudomonas aeruginosa, mucoidy and the chronic infection phenotype in cystic fibrosis. Trends Microbiol 3: 351356.
  • Desai M, Buhler T, Weller PH & Brown MR (1998) Increasing resistance of planktonic and biofilm cultures of Burkholderia cepacia to ciprofloxacin and ceftazidime during exponential growth. J Antimicrob Chemoth 42: 153160.
  • De Vries SP, Bootsma HJ, Hays JP & Hermans PW (2009) Molecular aspects of Moraxella catarrhalis pathogenesis. Microbiol Mol Biol R 73: 389406.
  • Di A, Brown ME, Deriy LV et al. (2006) CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol 8: 933944.
  • Di Sant'Agnese PA & Talamo RC (1967) Pathogenesis and physiopathology of cystic fibrosis of the pancreas. New Engl J Med 277: 12871294.
  • Dodge JA, Lewis PA, Stanton M & Wilsher J (2007) Cystic fibrosis mortality and survival in the UK: 1947–2003. Eur Respir J 29: 522526.
  • Döring G (1999) Perspectives of serine proteinase inhibitor therapy for α1-antitrypsin inhibitor deficiency and cystic fibrosis. Pediatr Pulm 28: 363375.
  • Döring G & Gulbins E (2009) Cystic fibrosis and innate immunity: how chloride channel mutations provoke lung disease. Cell Microbiol 11: 208216.
  • Döring G & Ratjen F (2005) Cystic fibrosis molecular cell biology. Encyclopedia of Molecular Cell Biology and Molecular Medicine, Vol. 8, 2nd edn (MeyersRA, ed), pp. 623640. Wiley-VCH, Weinheim.
  • Döring G & Ratjen F (2007) Immunology of cystic fibrosis. Cystic Fibrosis (HodsonM, GededsD & BushA, eds), pp. 6980. Hodder Arnold, London.
  • Döring G, Conway SP, Heijerman HGM et al. (2000) Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 16: 749767.
  • Döring G & Høiby Nthe Consensus Study Group (2004) Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 3: 6791.
  • Duan K, Sibley CD, Davidson CJ & Surette MG (2009) Chemical interactions between organisms in microbial communities. Contrib Microbiol 16: 117.
  • Eller J, Ede A, Schaberg T, Niederman MS, Mauch H & Lode H (1998) Infective exacerbations of chronic bronchitis. Chest 113: 15421548.
  • Engelhardt JF, Yankaskas JR, Ernst SA et al. (1992) Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat Genet 2: 240248.
  • Ernst RK, Yi EC, Guo L, Lim KB, Burns JL, Hackett M & Miller SI (1999) Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science 286: 15611565.
  • Erwin AL & Smith AL (2007) Nontypeable Haemophilus influenzae: understanding virulence and commensal behavior. Trends Microbiol 15: 355362.
  • Fagon JY, Chastre J, Trouillet JL, Domart Y, Dombret MC, Bornet M & Gibert C (1990) Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am Rev Respir Dis 142: 10041008.
  • Ferreira AS, Leitao JH, Silva IN, Pinheiro PF, Sousa SA, Ramos CG & Moreira LM (2010) Distribution of cepacian biosynthesis genes among environmental and clinical Burkholderia strains and role of cepacian exopolysaccharide in resistance to stress conditions. Appl Environ Microb 76: 441450.
  • Ferrer M, Ioanas M, Arancibia F, Marco MA, De La Bellacasa JP & Torres A (2005) Microbial airway colonization is associated with noninvasive ventilation failure in exacerbation of chronic obstructive pulmonary disease. Crit Care Med 33: 20032009.
  • Frederiksen B, Pressler T, Hansen A, Koch C & Hoiby N (2006) Effect of aerosolized rhDNase (pulmozyme) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatr 95: 10701074.
  • Gilles-Gonzalez MA & Gonzalez G (2005) Heme-based sensors: defining characteristics, recent developments, and regulatory hypotheses. J Inorg Biochem 99: 122.
  • Gilsdorf JR, Marrs CF & Foxman B (2004) Haemophilus influenzae: genetic variability and natural selection to identify virulence factors. Infect Immun 72: 24572461.
  • Goerke C & Wolz C (2004) Regulatory and genomic plasticity of Staphylococcus aureus during persistent colonization and infection. Int J Med Microbiol 294: 195202.
  • Goerke C, Campana S, Bayer MG et al. (2000) Direct quantitative transcript analysis of the agr regulon of Staphylococcus aureus during human infection in comparison to the expression profile in vitro. Infect Immun 68: 13041311.
  • Goerke C, Matias y Papenberg S, Dasbach S et al. (2004) Increased frequency of genomic alterations in Staphylococcus aureus during chronic infection is in part due to phage mobilization. J Infect Dis 189: 724734.
  • Govan JRW, Brown PH, Maddison J, Doherty CJ, Nelson JW, Dodd M, Greening AP & Webb AK (1993) Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 342: 1519.
  • Green J & Paget MS (2004) Bacterial redox sensors. Nat Rev Microbiol 2: 954966.
  • Greenberg SB, Allen M, Wilson J & Atmar RL (2000) Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Resp Crit Care 162: 167173.
  • Haggie PM & Verkman AS (2007) Cystic fibrosis transmembrane conductance regulator-independent phagosomal acidification in macrophages. J Biol Chem 282: 3142231428.
  • Haggie PM & Verkman AS (2009) Defective organellar acidification as a cause of cystic fibrosis lung disease – re-examination of a recurring hypothesis. Am J Physiol Lung-C 296: L859L867.
  • Hancock RE, Mutharia LM, Chan L, Darveau RP, Speert DP & Pier GB (1983) Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect Immun 42: 170177.
  • Harris JK, De Groote MA, Sagel SD, Zemanick ET, Kapsner R, Penvari C, Kaess H, Deterding RR, Accurso FJ & Pace NR (2007) Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. P Natl Acad Sci USA 104: 2052920533.
  • Hassett DJ, Sutton MD, Schurr MJ, Herr AB, Caldwell CC & Matu JO (2009) Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways. Trends Microbiol 17: 130138.
  • Häussler S, Tümmler B, Weissbrodt H, Rohde M & Steinmetz I (1999) Small-colony variants of Pseudomonas aeruginosa in cystic fibrosis. Clin Infect Dis 29: 621625.
  • Häussler S, Ziegler I, Lottel A, Von Götz F, Rohde M, Wehmhöhner D, Saravanamuthu S, Tümmler B & Steinmetz I (2003) Highly adherent small-colony variants of Pseudomonas aeruginosa in cystic fibrosis lung infection. J Med Microbiol 52: 295301.
  • Herbert S, Worlitzsch D, Dassy B et al. (1997) Regulation of the Staphylococcus aureus capsular polysaccharide type 5: CO2 inhibition in vitro and in vivo. J Infect Dis 176: 431438.
  • Hill AT, Bayley D & Stockley RA (1999a) The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Resp Crit Care 160: 893898.
  • Hill AT, Campbell EJ, Bayley DL, Hill SL & Stockley RA (1999b) Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ). Am J Resp Crit Care 160: 19681975.
  • Hill AT, Campbell EJ, Hill SL, Bayley DL & Stockley RA (2000) Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 109: 288295.
  • Hoboth C, Hoffmann R, Eichner A, Henke C, Schmoldt S, Imhof A, Heesemann J & Hogardt M (2009) Dynamics of adaptive microevolution of hypermutable Pseudomonas aeruginosa during chronic pulmonary infection in patients with cystic fibrosis. J Infect Dis 200: 118130.
  • Hoffman LR, Deziel E, D'Argenio DA, Lepine F, Emerson J, McNamara S, Gibson RL, Ramsey BW & Miller SI (2006) Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa. P Natl Acad Sci USA 103: 1989019895.
  • Hoffmann N, Rasmussen TB, Jensen PO, Stub C, Hentzer M, Molin S, Ciofu O, Givskov M, Johansen HK & Hoiby N (2005) Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis. Infect Immun 73: 25042514.
  • Hogardt M, Roeder M, Schreff AM, Eberl L & Heesemann J (2004) Expression of Pseudomonas aeruginosa exoS is controlled by quorum sensing and RpoS. Microbiology 150: 843851.
  • Hogardt M, Hoboth C, Schmoldt S, Henke C, Bader L & Heesemann J (2007) Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis. J Infect Dis 195: 7080.
  • Hogg JC & Timens W (2009) The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 4: 435459.
  • Hogg JC, Chu F, Utokaparch S et al. (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. New Engl J Med 350: 26452653.
  • Høiby N & Frederiksen B (2000) Microbiology of cystic fibrosis. Cystic Fibrosis (HodsonME & GeddesD, eds), pp. 83108. Arnold, London.
  • Jain M, Ramirez D, Seshadri R, Cullina JF, Powers CA, Schulert GS, Bar-Meir M, Sullivan CL, McColley SA & Hauser AR (2004) Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis. J Clin Microbiol 42: 52295237.
  • Jewes LA & Spencer RC (1990) The incidence of anaerobes in the sputum of patients with cystic fibrosis. J Med Microbiol 31: 271274.
  • Jones AM, Dodd ME & Webb AK (2001) Burkholderia cepacia: current clinical issues, environmental controversies and ethical dilemmas. Eur Respir J 17: 295301.
  • Joo NS, Lee DJ, Winges KM, Rustagi A & Wine JJ (2004) Regulation of antiprotease and antimicrobial protein secretion by airway submucosal gland serous cells. J Biol Chem 279: 3885438860.
  • Keatings VM, Collins PD, Scott DM & Barnes PJ (1996) Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Resp Crit Care 153: 530534.
  • Keller L & Surette MG (2006) Communication in bacteria: an ecological and evolutionary perspective. Nat Rev Microbiol 4: 249258.
  • Kerem BT, Rommens JM, Buchanan JA et al. (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245: 10731080.
  • Klepac-Ceraj V, Lemon KP, Marti TR et al. (2010) Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa. Environ Microbiol 12: 12931303.
  • Klockgether J, Würdemann D, Reva O, Wiehlmann L & Tümmler B (2007) Diversity of the abundant pKLC102/PAGI-2 family of genomic islands in Pseudomonas aeruginosa. J Bacteriol 189: 24432459.
  • Kolpen M, Hansen CR, Bjarnsholt T et al. (2010) The respiratory burst of polymorphonuclear leukocytes accelerates oxygen depletion in sputum from CF patients with chronic Pseudomonas aeruginosa lung infection. Thorax 65: 5762.
  • Kong KF, Vuong C & Otto M (2006) Staphylococcus quorum sensing in biofilm formation and infection. Int J Med Microbiol 296: 133139.
  • Konstan MW, Hilliard KA, Norvell TM & Berger M (1994) Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Resp Crit Care 150: 448454.
  • Kummerli R, Griffin AS, West SA, Buckling A & Harrison F (2009) Viscous medium promotes cooperation in the pathogenic bacterium Pseudomonas aeruginosa. P Roy Soc Lond B 276: 35313538.
  • Lee DG, Urbach JM, Wu G et al. (2006) Genomic analysis reveals that Pseudomonas aeruginosa virulence is combinatorial. Genome Biol 7: R90.
  • Lee VT, Smith RS, Tummler B & Lory S (2005) Activities of Pseudomonas aeruginosa effectors secreted by the Type III secretion system in vitro and during infection. Infect Immun 73: 16951705.
  • Lehrer RI & Ganz T (2002) Defensins of vertebrate animals. Curr Opin Immunol 14: 96102.
  • Lopez AD, Shibuya K, Rao C et al. (2006) Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 27: 397412.
  • Lory S, Merighi M & Hyodo M (2009) Multiple activities of c-di-GMP in Pseudomonas aeruginosa. Nucleic Acids Symp Ser 53: 5152.
  • Luzar MA, Thomassen MJ & Montie TC (1985) Flagella and motility alterations in Pseudomonas aeruginosa strains from patients with cystic fibrosis: relationship to patient clinical condition. Infect Immun 50: 577582.
  • Mahenthiralingam E, Campbell ME & Speert DP (1994) Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis. Infect Immun 62: 596605.
  • Mahenthiralingam E, Urban TA & Goldberg JB (2005) The multifarious,multireplicon Burkholderia cepacia complex. Nat Rev Microbiol 3: 144156.
  • Maiden MC (2006) Multilocus sequence typing of bacteria. Annu Rev Microbiol 60: 561588.
  • Mandsberg LF, Ciofu O, Kirkby N, Christiansen LE, Poulsen HE & Høiby N (2009) Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. Antimicrob Agents Ch 53: 24832491.
  • Martinez-Solano L, Macia MD, Fajardo A, Oliver A & Martinez JL (2008) Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin Infect Dis 47: 15261533.
  • Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW & Boucher RC (1998) Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95: 10051010.
  • Matsui H, Verghese MW, Kesimer M et al. (2005) Reduced three-dimensional motility in dehydrated airway mucus prevents neutrophil capture and killing bacteria on airway epithelial surfaces. J Immunol 175: 10901099.
  • McKenney D, Pouliot KL, Wang Y et al. (1999) Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 284: 15231527.
  • Miravitlles M, Espinosa C, Fernandez-Laso E, Martos JA, Maldonado JA & Gallego MStudy Group of Bacterial Infection in COPD (1999) Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 116: 4046.
  • Mitchell G, Brouillette E, Lalonde Séguin D, Asselin A-E, Lebeau Jacob C & Malouin F (2010) A role for sigma factor B in the emergence of Staphylococcus aureus small-colony variants and elevated biofilm production resulting from an exposure to aminoglycosides. Microbial Pathogenesis 48: 1827.
  • Monso E, Ruiz J, Rosell A, Manterola J, Fiz J, Morera J & Ausina V (1995) Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Resp Crit Care 152: 13161320.
  • Montanari S, Oliver A, Salerno P, Mena A, Cariani L, Bretoni G, Conese M, Tümmler B, Döring G & Bragonzi A (2007) Biological cost of hypermutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis. Microbiology 153: 14451454.
  • Murphy TF & Parameswaran G (2009) Moraxella catarrhalis, a human respiratory tract pathogen. Clin Infect Dis 49: 124131.
  • Murphy TF, Brauer AL, Schiffmacher AT & Sethi S (2004) Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Resp Crit Care 170: 266272.
  • Murphy TF, Brauer AL, Grant BJ & Sethi S (2005) Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Resp Crit Care 172: 195199.
  • Murphy TF, Brauer AL, Eschberger K, Lobbins P, Grove L, Cai X & Sethi S (2008) Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Resp Crit Care 177: 853860.
  • Nguyen D & Singh PK (2006) Evolving stealth: genetic adaptation of Pseudomonas aeruginosa during cystic fibrosis infections. P Natl Acad Sci USA 103: 83058306.
  • Nocker A, Burr M & Camper AK (2007) Genotypic microbial community profiling: a critical technical review. Microb Ecol 54: 276289.
  • Novick RP (2003) Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol Microbiol 48: 14291449.
  • Novick RP, Ross HF, Projan SJ, Kornblum J, Kreiswirth B & Moghazeh S (1993) Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule. EMBO J 12: 39673975.
  • Novick RP, Projan SJ, Kornblum J et al. (1995) The agr P2 operon: an autocatalytic sensory transduction system in Staphylococcus aureus. Mol Gen Genet 248: 446458.
  • Nseir S, Di Pompeo C, Cavestri B et al. (2006) Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: prevalence, risk factors, and outcome. Crit Care Med 34: 29592966.
  • Oliver A, Cantón R, Campo P, Baquero F & Blázquez J (2000) High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288: 12511254.
  • Oliver A, Baquero F & Blazquez J (2002) The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonasaeruginosa: molecular characterization of naturally occurring mutants. Mol Microbiol 43: 16411650.
  • Pamp SJ, Gjermansen M, Johansen HK & Tolker-Nielsen T (2008) Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol 68: 223240.
  • Parameswaran G, Wrona C, Murphy T & Sethi S (2009) Moraxella catarrhalis acquisition, airway inflammation and protease-antiprotease balance in chronic obstructive pulmonary disease. BMC Infect Dis 9: 178.
  • Perez Vidakovics ML & Riesbeck K (2009) Virulence mechanisms of Moraxella in the pathogenesis of infection. Curr Opin Infect Dis 22: 279285.
  • Pier GB (2000) Role of the CF transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections. P Natl Acad Sci USA 97: 88228828.
  • Pollock JD, Williams DA, Gifford MAC et al. (1995) Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat Genet 9: 202209.
  • Prunier AL, Malbruny B, Laurans M, Brouard J, Duhamel JF & Leclercq R (2003) High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J Infect Dis 187: 17091716.
  • Quon BS, Gan WQ & Sin DD (2008) Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis. Chest 133: 756766.
  • Rahman I & MacNee W (1996) Oxidant/antioxidant imbalance in smokers and chronic obstructive pulmonary disease. Thorax 51: 348350.
  • Rakhimova E, Wiehlmann L, Brauer AL, Sethi S, Murphy TF & Tummler B (2009) Pseudomonas aeruginosa population biology in chronic obstructive pulmonary disease. J Infect Dis 200: 19281935.
  • Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J & Barnes NC (2006) Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Db Syst Rev 2: CD004403.
  • Ramsey DM & Wozniak DJ (2005) Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis. Mol Microbiol 56: 309322.
  • Ratjen F, Hartog CM, Paul K, Wermelt J & Braun J (2002) Matrix metalloproteases in BAL fluid of cystic fibrosis patients and their modulation by treatment with dornase alpha. Thorax 57: 930934.
  • Rau MH, Hansen SK, Johansen HK, Thomsen LE, Workman CT, Nielsen KF, Jelsbak L, Høiby N, Yang L & Molin S (2010) Early adaptive developments of Pseudomonas aeruginosa after the transition from life in the environment to persistent colonization in the airways of human cystic fibrosis hosts. Environ Microbiol April 7. Epub ahead of print.
  • Riedel K, Hentzer M, Geisenberger O, Huber B, Steidle A, Wu H, Høiby N, Givskov M, Molin S & Eberl L (2001) N-acylhomoserine-lactone-mediated communication between Pseudomonas aeruginosa and Burkholderia cepacia in mixed biofilms. Microbiology 147: 32493262.
  • Riethmüller J, Anthonysamy J, Serra E, Schwab M, Döring G & Gulbins E (2009) Therapeutic efficacy and safety of amitriptyline in patients with cystic fibrosis. Cell Physiol Biochem 24: 6572.
  • Riordan JR, Rommens JM, Kerem BS et al. (1989) Identification of the Cystic Fibrosis Gene: Cloning and characterization of complementary DNA. Science 245: 10661073.
  • Roede BM, Bresser P, Prins JM, Schellevis F, Verheij TJ & Bindels PJ (2009) Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD. Eur Respir J 33: 282288.
  • Rogers GB, Hart CA, Mason JR et al. (2003) Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal reobligation fragment length polymorphism profiling. J Clin Microbiol 41: 35483558.
  • Rogers GB, Carroll MP, Serisier DJ et al. (2004) Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16S ribosomal DNA terminal reobligation fragment length polymorphism profiling. J Clin Microbiol 42: 51765183.
  • Rogers GB, Carroll MP, Serisier DJ et al. (2006) Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis. J Clin Microbiol 44: 26012604.
  • Rogers GB, Carroll MP & Bruce KD (2009) Studying bacterial infections through culture-independent approaches. J Med Microbiol 58: 14011418.
  • Roman F, Canton R, Perez-Vazquez M, Baquero F & Campos J (2004) Dynamics of long-term colonization of respiratory tract by Haemophilus influenzae in cystic fibrosis patients shows a marked increase in hypermutable strains. J Clin Microbiol 42: 14501459.
  • Rommens JM, Iannuzzi MC, Kerem BS et al. (1989) Identification of the Cystic Fibrosis Gene: Chromosome walking and jumping. Science 245: 10591065.
  • Rosell A, Monso E, Soler N et al. (2005) Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 165: 891897.
  • Sabra W, Lunsdorf H & Zeng AP (2003) Alterations in the formation of lipopolysaccharide and membrane vesicles on the surface of Pseudomonas aeruginosa PAO1 under oxygen stress conditions. Microbiology 149: 27892795.
  • Sadowska B, Bonar A, Von Eiff C et al. (2002) Characteristics of Staphylococcus aureus, isolated from airways of cystic fibrosis patients, and their small colony variants. FEMS Immunol Med Mic 32: 191197.
  • Sahly H, Schubert S, Harder J, Rautenberg P, Ullmann U, Schroder H & Podschun R (2003) Burkholderia is highly resistant to human beta-defensin 3. Antimicrob Agents Ch 47: 17391741.
  • Salunkhe P, Smart CH, Morgan JA, Panagea S, Walshaw MJ, Hart CA, Geffers R, Tümmler B & Winstanley C (2005a) A cystic fibrosis epidemic strain of Pseudomonas aeruginosa displays enhanced virulence and antimicrobial resistance. J Bacteriol 187: 49084920.
  • Salunkhe P, Töpfer T, Buer J & Tümmler B (2005b) Genome-wide transcriptional profiling of the steady-state response of Pseudomonas aeruginosa to hydrogen peroxide. J Bacteriol 187: 25652572.
  • Schneider M, Muhlemann K, Droz S, Couzinet S, Casaulta C & Zimmerli S (2008) Clinical characteristics associated with isolation of small-colony variants of Staphylococcus aureus and Pseudomonas aeruginosa from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol 46: 18321834.
  • Schweda EK, Richards JC, Hood DW & Moxon ER (2007) Expression and structural diversity of the lipopolysaccharide of Haemophilus influenzae: implication in virulence. Int J Med Microbiol 297: 297306.
  • Seemungal T, Harper-Owen R, Bhowmik A et al. (2001) Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Resp Crit Care 164: 16181623.
  • Seemungal TAR, Wilkinson TMA, Hurst JR, Perera WR, Sapsford RJ & Wedzicha JA (2008) Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Resp Crit Care 178: 11391147.
  • Segal BH, Ding L & Holland SM (2003) Phagocyte NADPH oxidase, but not inducible nitric oxide synthase, is essential for early control of Burkholderia cepacia and Chromobacterium violaceum infection in mice. Infect Immun 71: 205210.
  • Selsted ME & Quellette AJ (2003) Mammalian defensins in the antimicrobial immune response. Nat Immunol 6: 551557.
  • Sethi S & Murphy TF (2001) Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 14: 336363.
  • Sethi S & Murphy TF (2008) Infection in the pathogenesis and course of chronic obstructive pulmonary disease. New Engl J Med 359: 23552365.
  • Sethi S, Evans N, Grant BJ & Murphy TF (2002) New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. New Engl J Med 347: 465471.
  • Sethi S, Wrona C, Eschberger K, Lobbins P, Cai X & Murphy TF (2008) Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Resp Crit Care 177: 491497.
  • Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC & Surette MG (2008) A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. P Natl Acad Sci USA 105: 1507015075.
  • Sibley CD, Parkins MD, Rabin HR & Surette MG (2009) The relevance of the polymicrobial nature of airway infection in the acute and chronic management of patients with cystic fibrosis. Curr Opin Investig D 10: 787794.
  • Silo-Suh L, Suh SJ, Phibbs PV & Ohman DE (2005) Adaptations of Pseudomonas aeruginosa to the cystic fibrosis lung environment can include deregulation of zwf, encoding glucose-6-phosphate dehydrogenase. J Bacteriol 187: 75617568.
  • Silverman EK, Spira A & Pare PD (2009) Genetics and genomics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 6: 539542.
  • Slevogt H, Zabel S, Opitz B et al. (2008) CEACAM1 inhibits toll-like receptor 2-triggered antibacterial responses of human pulmonary epithelial cells. Nat Immunol 9: 12701278.
  • Smith EE, Buckley DG, Wu Z et al. (2006) Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. P Natl Acad Sci USA 103: 84878492.
  • Smolonska J, Wijmenga C, Postma DS & Boezen HM (2009) Meta-analyses on suspected chronic obstructive pulmonary disease genes: a summary of 20 years' research. Am J Resp Crit Care 180: 618631.
  • Soler N, Torres A, Ewig S et al. (1998) Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Resp Crit Care 157: 14981505.
  • Soler N, Ewig S, Torres A, Filella X, Gonzalez J & Zaubet A (1999) Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 14: 10151022.
  • Soler N, Agusti C, Angrill J, Puig De la Bellacasa J & Torres A (2007) Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 62: 2935.
  • Sousa S, Ulrich M, Bragonzi A, Burke M, Worlitzsch D, Leitão JH, Meisner C, Eberl L, Sá-Correia I & Döring G (2007) Virulence of Burkholderia cepacia complex strains in gp91phox−/− mice. Cell Microbiol 9: 28172825.
  • Speert DP, Bond M, Woodman RC & Curnutte JT (1994) Infection with Pseudomonas cepacia in chronic granulomatous disease: role of nonoxidative killing by neutrophils in host defense. J Infect Dis 170: 15241531.
  • Srikhanta YN, Fox KL & Jennings MP (2010) The phasevarion: phase variation of type III DNA methyltransferases controls coordinated switching in multiple genes. Nat Rev Microbiol 8: 196206.
  • Starkey M, Hickman JA, Ma L et al. (2009) Pseudomonas aeruginosa Rugose Small-Colony Variants Have Adaptations That Likely Promote Persistence in the Cystic Fibrosis Lung. J Bacteriol 191: 34923503.
  • Starner TD, Zhang N, Kim GH, Apicella MA & McCray PB Jr (2006) Haemophilus influenzae forms biofilms on airway epithelia: implications in cystic fibrosis. Am J Resp Crit Care 174: 213220.
  • Stockley RA (1999) Neutrophils and protease/antiprotease imbalance. Am J Resp Crit Care 160: S49S52.
  • Stover CK, Pham XQ, Erwin AL et al. (2000) Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406: 959964.
  • Suh SJ, Silo-Suh L, Woods DE, Hassett DJ, West SE & Ohman DE (1999) Effect of rpoS mutation on the stress response and expression of virulence factors in Pseudomonas aeruginosa. J Bacteriol 181: 38903897.
  • Taddei F, Radman M, Maynard-Smith J, Toupance B, Gouyon PH & Godelle B (1997) Role of mutator alleles in adaptive evolution. Nature 387: 700702.
  • Taylor RF, Hodson ME & Pitt TL (1993) Adult cystic fibrosis: association of acute pulmonary exacerbations and increasing severity of lung disease with auxotrophic mutants of Pseudomonas aeruginosa. Thorax 48: 10021005.
  • Teichgräber V, Ulrich M, Riethmüller J et al. (2008) Ceramide accumulation mediates inflammation, cell death and infection susceptibility in CF. Nat Med 14: 382391.
  • Thomas SR, Ray A, Hodson ME & Pitt TL (2000) Increased sputum amino acid concentrations and auxotrophy of Pseudomonas aeruginosa in severe cystic fibrosis lung disease. Thorax 55: 795797.
  • Thomassen MJ, Demko CA, Boxerbaum B, Stern RC & Kuchenbrod PJ (1979) Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J Infect Dis 140: 873880.
  • Tosi MF, Zakem H & Berger M (1990) Neutrophil elastase cleaves C3bi on opsonized Pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest 86: 300308.
  • Tümmler B (2006) Clonal variations in Pseudomonas aeruginosa. Pseudomonas: Molecular Biology of Emerging Issues (RamosJL & LevesqueR, eds), pp. 3568. Springer, Heidelberg.
  • Tunney MM, Field TR, Moriarty TF et al. (2008) Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Resp Crit Care 177: 9951001.
  • Ulrich M, Herbert S, Berger J, Bellon G, Louis D, Münker G & Döring G (1998) Localization of Staphylococcus aureus in infected airways of patients with CF and in a cell culture model of S. aureus adherence. Am J Resp Crit Care 19: 8391.
  • Ulrich M, Bastian M, Cramton SE et al. (2007) The staphylococcal respiratory response regulator SrrAB induces ica gene transcription and PIA expression, protecting Staphylococcus aureus from neutrophil killing under anaerobic growth conditions. Mol Microbiol 65: 12761287.
  • Ulrich M, Worlitzsch D, Viglio S et al. (2010) Alveolar inflammation in cystic fibrosis. J Cyst Fibros 9: 217227.
  • Van Delden C (2004) Virulence factors of Pseudomonas aeruginosa. Pseudomonas: Virulence and Gene Regulation, Vol. 2 (RamosJ-L, ed), pp. 346. Kluwer Academics/Plenum Publishers, New York.
  • Verkman AS, Song Y & Thiagarajah JR (2003) Role of airway surface liquid and submucosal glands in CF lung disease. Am J Physiol-Cell Ph 284: C2C15.
  • Vinion-Dubiel AD & Goldberg JB (2003) Lipopolysaccharide of Burkholderia cepacia complex. J Endotoxin Res 9: 201213.
  • Von Eiff C (2008) Staphylococcus aureus small colony variants: a challenge to microbiologists and clinicians. Int J Antimicrob Agents 31: 507510.
  • Watson ME Jr, Burns JL & Smith AL (2004) Hypermutable Haemophilus influenzae with mutations in mutS are found in cystic fibrosis sputum. Microbiology 150: 29472958.
  • Wehmhöner D, Häussler S, Tümmler B, Jänsch L, Bredenbruch F, Wehland J & Steinmetz I (2003) Inter- and intraclonal diversity of the Pseudomonas aeruginosa proteome manifests within the secretome. J Bacteriol 185: 58075814.
  • Whitchurch CB, Tolker-Nielsen T, Ragas PC & Mattick JS (2002) Extracellular DNA required for bacterial biofilm formation. Science 295: 1487.
  • White AJ, Gompertz S, Bayley DL, Hill SL, O'Brien C, Unsal I & Stockley RA (2003) Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 58: 680685.
  • Wiehlmann L, Wagner G, Cramer N et al. (2007) Population structure of Pseudomonas aeruginosa. P Natl Acad Sci USA 104: 81018106.
  • Williams P & Camara M (2009) Quorum sensing and environmental adaptation in Pseudomonas aeruginosa: a tale of regulatory networks and multifunctional signal molecules. Curr Opin Microbiol 12: 182191.
  • Wimpenny J, Manz W & Szewzyk U (2000) Heterogeneity in biofilms. FEMS Microbiol Rev 24: 661671.
  • Winstanley C & Fothergill JL (2009) The role of quorum sensing in chronic cystic fibrosis Pseudomonas aeruginosa infections. FEMS Microbiol Lett 290: 19.
  • Wood AM & Stockley RA (2006) The genetics of chronic obstructive pulmonary disease. Respir Res 7: 130.
  • Woods DE, Schaffer MS, Rabin HR, Campbell GD & Sokol PA (1986) Phenotypic comparison of Pseudomonas aeruginosa strains isolated from a variety of clinical sites. J Clin Microbiol 24: 260264.
  • Worlitzsch D, Tarran R, Ulrich M et al. (2002) Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109: 317325.
  • Worlitzsch D, Rintelen C, Böhm K et al. (2009) Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Clin Microbiol Infec 15: 454460.
  • Xu KD, Stewart PS, Xia F, Huang CT & McFeters GA (1998) Spatial physiological heterogeneity in Pseudomonas aeruginosa biofilm is determined by oxygen availability. Appl Environ Microb 64: 40354039.